[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 542
1. Jang SY, Kong MH, Song KY, Frazee JG: Intracranial Metastases of Cervical Intramedullary Low-Grade Astrocytoma without Malignant Transformation in Adult. J Korean Neurosurg Soc; 2009 Jun;45(6):381-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intracranial Metastases of Cervical Intramedullary Low-Grade Astrocytoma without Malignant Transformation in Adult.
  • The first case of intracranial metastases of a cervical intramedullary low-grade astrocytoma without malignant transformation in adult is presented in this report.
  • Seven years ago, a 45 year-old male patient underwent biopsy to confirm pathologic characteristics and received craniocervical radiation and chemotherapy for a grade II astrocytoma in the cervical spinal cord.
  • The tumor at the cervical and brain lesions was classified as an astrocytoma (WHO grade II).
  • When a patient with low-grade astrocytoma in the spinal cord has new cranial symptoms after surgery, radiaton, and chemotherapy, the possibility of its metastasis should be suspected because it can spread to the intracranial cavity even without malignant transformation as shown in this case.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurooncol. 2000 Dec;50(3):239-43 [11263503.001]
  • [Cites] J Clin Neurosci. 2001 Jul;8(4):374-7 [11437586.001]
  • [Cites] Spinal Cord. 2006 Dec;44(12):740-5 [16670687.001]
  • [Cites] Childs Nerv Syst. 2005 Jun;21(6):477-81 [15378329.001]
  • [Cites] Neurosurgery. 2005;56(1):191 [15617606.001]
  • [Cites] Med Pediatr Oncol. 1997 Dec;29(6):560-2 [9324344.001]
  • [Cites] Neurosurgery. 1997 Jan;40(1):141-51 [8971836.001]
  • [Cites] J Neurooncol. 1995;25(3):245-50 [8592175.001]
  • [Cites] J Neurosurg. 1995 Sep;83(3):480-5 [7666226.001]
  • [Cites] J Neurosurg. 1995 Oct;83(4):590-5 [7674006.001]
  • [Cites] J Neurosurg. 1995 Jul;83(1):67-71 [7782852.001]
  • [Cites] J Neurooncol. 1994;18(1):49-52 [8057134.001]
  • [Cites] Neurol Med Chir (Tokyo). 1992 May;32(5):281-4 [1378944.001]
  • [Cites] J Neurosurg. 1992 Sep;77(3):355-9 [1506881.001]
  • [Cites] J Neurosurg. 1988 Aug;69(2):295-300 [3392575.001]
  • [Cites] Cancer. 1982 Aug 15;50(4):732-5 [7093908.001]
  • [Cites] Br J Surg. 1975 Feb;62(2):92-5 [1115920.001]
  • [Cites] Pediatr Blood Cancer. 2004 Nov;43(6):629-32 [15390309.001]
  • [Cites] Childs Nerv Syst. 2004 Feb;20(2):114-8 [14762681.001]
  • [Cites] Cancer. 2003 Aug 1;98(3):554-61 [12879473.001]
  • [Cites] Curr Opin Neurol. 2001 Dec;14(6):679-82 [11723373.001]
  • [Cites] Surg Neurol. 2001 Jul;56(1):39-41 [11546571.001]
  • [Cites] J Neurosurg. 2006 Dec;105(6 Suppl):508-14 [17184088.001]
  • (PMID = 19609424.001).
  • [ISSN] 2005-3711
  • [Journal-full-title] Journal of Korean Neurosurgical Society
  • [ISO-abbreviation] J Korean Neurosurg Soc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2711238
  • [Keywords] NOTNLM ; Astrocytoma / Cranial metastases / Intramedullary / Spinal cord tumor
  •  go-up   go-down


2. Chen AY, Lee H, Hartman J, Greco C, Ryu JK, O'Donnell R, Boggan J: Secondary supratentorial primitive neuroectodermal tumor following irradiation in a patient with low-grade astrocytoma. AJNR Am J Neuroradiol; 2005 Jan;26(1):160-2
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secondary supratentorial primitive neuroectodermal tumor following irradiation in a patient with low-grade astrocytoma.
  • We report a case of a supratentorial primitive neuroectodermal tumor (PNET) that occurred 12 years after cranial irradiation for a grade II astrocytoma.
  • Pathologic review assisted by immunohistochemical staining, however, revealed a high-grade PNET.
  • [MeSH-major] Astrocytoma / radiotherapy. Brain Neoplasms / radiotherapy. Cranial Irradiation. Frontal Lobe. Image Processing, Computer-Assisted. Magnetic Resonance Imaging. Neoplasms, Radiation-Induced / diagnosis. Neoplasms, Second Primary / diagnosis. Neuroectodermal Tumors, Primitive / diagnosis. Supratentorial Neoplasms / diagnosis. Tomography, X-Ray Computed


3. Payne CA, Maleki S, Messina M, O'Sullivan MG, Stone G, Hall NR, Parkinson JF, Wheeler HR, Cook RJ, Biggs MT, Little NS, Teo C, Robinson BG, McDonald KL: Loss of prostaglandin D2 synthase: a key molecular event in the transition of a low-grade astrocytoma to an anaplastic astrocytoma. Mol Cancer Ther; 2008 Oct;7(10):3420-8
SciCrunch. ArrayExpress: Data: Microarray .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Loss of prostaglandin D2 synthase: a key molecular event in the transition of a low-grade astrocytoma to an anaplastic astrocytoma.
  • This finding has exciting implications for early interventional efforts for the grade 2 and 3 astrocytomas.
  • [MeSH-major] Astrocytoma / enzymology. Astrocytoma / pathology. Intramolecular Oxidoreductases / deficiency

  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18852145.001).
  • [ISSN] 1535-7163
  • [Journal-full-title] Molecular cancer therapeutics
  • [ISO-abbreviation] Mol. Cancer Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclooxygenase Inhibitors; 0 / Lipocalins; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human; EC 5.3.- / Intramolecular Oxidoreductases; EC 5.3.99.2 / prostaglandin R2 D-isomerase; RXY07S6CZ2 / Prostaglandin D2
  •  go-up   go-down


Advertisement
4. Yap L, Crooks D, Warnke P: Low grade astrocytoma of the pituitary stalk. Acta Neurochir (Wien); 2007 Mar;149(3):307-11; discussion 311-2
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low grade astrocytoma of the pituitary stalk.
  • A case of low grade astrocytoma (WHO grade II) localised in the pituitary stalk is reported in a 46 year old female who presented with central diabetes insipidus.
  • [MeSH-major] Astrocytoma / surgery. Pituitary Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17242848.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Austria
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein; 0 / Ki-67 Antigen
  •  go-up   go-down


5. Rashid MH, Ahmad SU, Rahman MH, Raihan MZ, Sayed MA: Surgical outcome of low grade astrocytoma of brain. Mymensingh Med J; 2010 Apr;19(2):185-90
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical outcome of low grade astrocytoma of brain.
  • This study was carried out in the department of Neurosurgery, Dhaka Medical College Hospital, Dhaka, Bangladesh, during the period of January 2003 to December 2006 to elucidate the effectiveness of surgical treatment in the management of low grade astrocytoma of brain.
  • For this purpose, a total number of 50 cases admitted during the study period with low grade astrocytoma of brain supported by clinical features and radiological investigations (CT and MRI scan) were included in this study.
  • Out of 50 patients 60.0% had gross total removal of tumor and 40.0% sub total tumor resection.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20395910.001).
  • [ISSN] 1022-4742
  • [Journal-full-title] Mymensingh medical journal : MMJ
  • [ISO-abbreviation] Mymensingh Med J
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Bangladesh
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


6. Xiangsong Z, Changhong L, Weian C, Dong Z: PET Imaging of cerebral astrocytoma with 13N-ammonia. J Neurooncol; 2006 Jun;78(2):145-51
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PET Imaging of cerebral astrocytoma with 13N-ammonia.
  • We performed this study in order to assess the clinical potential of (13)N-ammonia PET in patients with cerebral astrocytoma.
  • RESULTS: Six out of nine cases of low-grade gliomas were detected with 13N-ammonia PET, and three non-astrocytoma low-grade gliomas were not detected with 13N-ammonia PET.
  • All 11 high-grade astrocytomas exhibited markedly increased uptake of 13N-ammonia.
  • The five non-neoplastic lesions exhibited low uptake, low T/W ratios and low PI.
  • The significant differences were observed between high-grade and low-grade gliomas with respect to both the T/W ratios and PI (T/W ratios: 5.92+/-2.27, n=11 vs. 1.66+/-0.61, n=9, P<0.01; PI: 5.22+/-1.67, n=11 vs. 1.60+/-0.54, n=9, P<0.01).
  • There were the significant differences between the T/W ratios and PI in low-grade astrocytomas and that in non-neoplastic lesions (T/W ratios: 2.00+/-0.42, n=6 vs. 0.97+/-0.11, n=5, P<0.01; PI: 1.89+/-0.37, n=6 vs. 0.99+/-0.03, n=5, P<0.01).
  • 13N-ammonia PET may enable differentiation between low- and high-grade astrocytomas, and has the potential to enable differentiation between low-grade astrocytomas and non-neoplastic lesions.
  • [MeSH-major] Ammonia. Astrocytoma / diagnostic imaging. Brain Neoplasms / diagnostic imaging. Nitrogen Isotopes. Positron-Emission Tomography / methods

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. Ammonia .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Nucl Med. 2001 Nov;28(11):1664-70 [11702108.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2002 Feb;29(2):176-82 [11926379.001]
  • [Cites] J Neurol Sci. 1995 Sep;132(1):20-7 [8523026.001]
  • [Cites] Neuropathol Appl Neurobiol. 1982 May-Jun;8(3):227-36 [6126838.001]
  • [Cites] Semin Nucl Med. 2003 Apr;33(2):148-62 [12756647.001]
  • [Cites] Circulation. 1980 Jan;61(1):34-43 [7349940.001]
  • [Cites] J Magn Reson Imaging. 1996 May-Jun;6(3):437-44 [8724408.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Dec 1;36(5):1251-61 [8985051.001]
  • [Cites] J Biol Chem. 1979 Jun 25;254(12):4982-92 [36379.001]
  • [Cites] J Nucl Med. 1976 Jun;17(6):473-9 [1262965.001]
  • [Cites] J Neurosurg. 1996 Mar;84(3):449-58 [8609557.001]
  • [Cites] J Nucl Med. 1976 Jul;17(7):603-12 [818345.001]
  • [Cites] Cancer. 1994 May 1;73(9):2386-94 [8168042.001]
  • [Cites] Br J Radiol. 1982 Nov;55(659):797-804 [6982741.001]
  • [Cites] Circulation. 1981 Jun;63(6):1259-72 [7226473.001]
  • [Cites] Radiology. 1993 Jan;186(1):45-53 [8380108.001]
  • [Cites] Nat Med. 1996 Mar;2(3):323-5 [8612232.001]
  • [Cites] No To Shinkei. 1993 Apr;45(4):362-8 [8101449.001]
  • [Cites] Stroke. 1981 Sep-Oct;12(5):607-19 [7303045.001]
  • [Cites] Neuroimaging Clin N Am. 1999 Nov;9(4):651-69 [10517938.001]
  • [Cites] Neuropathol Appl Neurobiol. 1990 Jun;16(3):205-11 [1976235.001]
  • (PMID = 16739028.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Nitrogen Isotopes; 0 / Radiopharmaceuticals; 7664-41-7 / Ammonia
  •  go-up   go-down


7. Facoetti A, Ranza E, Nano R: Proliferation and programmed cell death: role of p53 protein in high and low grade astrocytoma. Anticancer Res; 2008 Jan-Feb;28(1A):15-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proliferation and programmed cell death: role of p53 protein in high and low grade astrocytoma.
  • p53 is a cell cycle regulator that has been well-recognized as the key molecule that triggers the induction and the control of cell proliferation and apoptosis in a wide variety of tumours, including astrocytoma.
  • The aim of this study was to investigate the correlation of p53 expression with the apoptotic index (AI) and the cell proliferation index (PI) in pilocytic astrocytoma (PA) and glioblastoma multiforme (GBM).
  • A correlation of p53 expression with AI and PI was found in pilocytic astrocytoma but not in glioblastoma, probably because of the mutated p53 phenotype in the latter.
  • [MeSH-major] Apoptosis / physiology. Astrocytoma / pathology. Central Nervous System Neoplasms / pathology. Tumor Suppressor Protein p53 / biosynthesis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18383819.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


8. Radulović D: [Natural history of supratentorial low-grade astrocytoma: case report]. Srp Arh Celok Lek; 2006 Nov-Dec;134(11-12):537-40
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Natural history of supratentorial low-grade astrocytoma: case report].
  • Low-grade astrocytomas comprise a group of primary brain neoplasms with relatively low anaplastic potential, although through time they tend to behave more aggressively.
  • This report presents a natural history of a patient with low grade astrocytoma.
  • Initial computerized tomography and magnetic resonance of brain revealed oval, 4 cm in diameter, lesion in the left parietal region that was considered as low-grade glioma.
  • The described patient with low-grade astrocytoma lived without any oncological treatment eight years and four months from the time when diagnosis was made until intracranial herniation.
  • The natural history of disease in presented patient indicated that rational therapeutic strategy, for low-grade astrocytoma with epilepsy only, would be deferral of surgery until the time of manifestation of neurological or radiological deterioration.
  • [MeSH-major] Astrocytoma. Brain Neoplasms. Parietal Lobe

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17304770.001).
  • [ISSN] 0370-8179
  • [Journal-full-title] Srpski arhiv za celokupno lekarstvo
  • [ISO-abbreviation] Srp Arh Celok Lek
  • [Language] srp
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Serbia and Montenegro
  •  go-up   go-down


9. Giffoni SD, Cendes F, Valente M, Gil-da-Silva-Lopes VL: Midline facial defects with hypertelorism and low-grade astrocytoma: a previously undescribed association. Cleft Palate Craniofac J; 2006 Nov;43(6):748-51
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Midline facial defects with hypertelorism and low-grade astrocytoma: a previously undescribed association.
  • We report on a child with midline facial defects with hypertelorism (MFDH), median cleft lip, sphenoidal ventriculocele, partial agenesis of the corpus callosum, and low-grade astrocytoma in the cervicomedullary junction.
  • [MeSH-major] Astrocytoma / complications. Brain Neoplasms / complications. Craniofacial Abnormalities / complications. Hypertelorism / complications


10. Robinson CG, Prayson RA, Hahn JF, Kalfas IH, Whitfield MD, Lee SY, Suh JH: Long-term survival and functional status of patients with low-grade astrocytoma of spinal cord. Int J Radiat Oncol Biol Phys; 2005 Sep 1;63(1):91-100
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term survival and functional status of patients with low-grade astrocytoma of spinal cord.
  • PURPOSE: To determine survival and changes in neurologic function and Karnofsky performance status (KPS) in a series of patients treated for low-grade astrocytoma of the spinal cord during the past two decades.
  • METHODS: This study consisted of 14 patients with pathologically confirmed low-grade astrocytoma of the spinal cord who were treated between 1980 and 2003.
  • [MeSH-major] Astrocytoma / mortality. Spinal Cord Neoplasms / mortality

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16111576.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. van den Bent MJ, Afra D, de Witte O, Ben Hassel M, Schraub S, Hoang-Xuan K, Malmström PO, Collette L, Piérart M, Mirimanoff R, Karim AB, EORTC Radiotherapy and Brain Tumor Groups and the UK Medical Research Council: Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet; 2005 Sep 17-23;366(9490):985-90
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial.
  • BACKGROUND: Postoperative policies of "wait-and-see" and radiotherapy for low-grade glioma are poorly defined.
  • Patients with low-grade astrocytoma, oligodendroglioma, mixed oligoastrocytoma, and incompletely resected pilocytic astrocytoma, with a WHO performance status 0-2 were eligible.
  • Radiotherapy could be deferred for patients with low-grade glioma who are in a good condition, provided they are carefully monitored.
  • [MeSH-major] Astrocytoma / radiotherapy. Central Nervous System Neoplasms / radiotherapy. Oligodendroglioma / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Disease Progression. Disease-Free Survival. Female. Humans. Male. Middle Aged. Radiotherapy Dosage. Survival Rate

  • Genetic Alliance. consumer health - Oligodendroglioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Lancet Oncol. 2005 Dec;6(12):921; author reply 922 [16321759.001]
  • [ErratumIn] Lancet. 2006 Jun 3;367(9525):1818
  • (PMID = 16168780.001).
  • [ISSN] 1474-547X
  • [Journal-full-title] Lancet (London, England)
  • [ISO-abbreviation] Lancet
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 5U10 CA11488-; United States / NCI NIH HHS / CA / 5U10 CA11488-16
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  •  go-up   go-down


12. Pal D, Hall G, Loughrey C, Shivane A, Chakrabarty A, Chumas P: Primitive neuroectodermal tumour arising within low grade astrocytoma: transformation, de novo or radiation induced? Report of three cases and review of literature. Br J Neurosurg; 2008 Jun;22(3):402-8
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primitive neuroectodermal tumour arising within low grade astrocytoma: transformation, de novo or radiation induced? Report of three cases and review of literature.
  • The transformation from low grade to aggressive astrocytoma is well known.
  • However, the development of a completely different tumour such as a primitive neuroectodermal tumour (PNET) within a low grade astrocytoma (LGA) is rare.
  • All three patients had histologically proven low-grade astrocytoma and received radiotherapy following biopsy.
  • Two patients underwent partial resection for recurrence, one at five and the other ten years later with histological confirmation of low-grade astrocytoma.
  • Histology now revealed high grade PNET.
  • Among the six reported cases of PNET arising following prophylactic radiation therapy to low grade astrocytomas, only two occurred within the original tumour.
  • Whether these cases represent transformation of low-grade astrocytoma, de novo formation of new tumour or radiation induced neoplasm is uncertain.
  • [MeSH-major] Astrocytoma / radiotherapy. Brain Neoplasms / radiotherapy. Neoplasms, Radiation-Induced / etiology. Neoplasms, Second Primary / etiology. Neuroectodermal Tumors, Primitive / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18568729.001).
  • [ISSN] 0268-8697
  • [Journal-full-title] British journal of neurosurgery
  • [ISO-abbreviation] Br J Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 14
  •  go-up   go-down


13. Rivera-Luna R, Zapata-Tarrés M, Medina-Sansón A, López-Aguilar E, Niembro-Zúñiga A, Amador Zarco J, Marhx-Bracho A, Rueda-Franco F, Bornstein-Quevedo L: Long-term survival in children under 3 years of age with low-grade astrocytoma. Childs Nerv Syst; 2007 May;23(5):543-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term survival in children under 3 years of age with low-grade astrocytoma.
  • OBJECTIVE: The purpose of this study is to analyze clinical aspects and disease-free survival (DFS) in children less than 3 years of age diagnosed with low-grade astrocytoma.
  • Twenty-three patients had pilocytic astrocytoma, 18 diffused, and 2 mixed.
  • [MeSH-major] Astrocytoma / therapy. Brain Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Child, Preschool. Combined Modality Therapy. Disease Progression. Female. Humans. Infant. Infant, Newborn. Male. Neurosurgical Procedures. Postoperative Complications / epidemiology. Retrospective Studies. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Neurol. 1985 Jan;23(1):64-8 [3964979.001]
  • [Cites] Cancer. 2003 Sep 15;98(6):1243-52 [12973849.001]
  • [Cites] Neurosurgery. 1992 Jan;30(1):58-62; discussion 62-3 [1738456.001]
  • [Cites] Klin Padiatr. 2004 Nov-Dec;216(6):331-42 [15565548.001]
  • [Cites] J Pediatr Hematol Oncol. 2003 May;25(5):372-8 [12759623.001]
  • [Cites] Clin Neuropathol. 2004 Jan-Feb;23(1):21-7 [14986930.001]
  • [Cites] Med Pediatr Oncol. 1999 Dec;33(6):572-6 [10573582.001]
  • [Cites] Childs Brain. 1976;2(3):177-86 [971637.001]
  • [Cites] Prog Exp Tumor Res. 1987;30:160-9 [3628802.001]
  • [Cites] Pediatr Blood Cancer. 2004 Nov;43(6):629-32 [15390309.001]
  • [Cites] J Clin Oncol. 1992 Feb;10(2):249-56 [1732426.001]
  • [Cites] J Neurooncol. 1989 Nov;7(4):367-71 [2511279.001]
  • [Cites] Acta Neuropathol. 2004 Jul;108(1):49-56 [15118874.001]
  • [Cites] Childs Nerv Syst. 2003 Nov;19(10-11):729-35 [14631523.001]
  • [Cites] Neurology. 1986 May;36(5):597-601 [3703257.001]
  • [Cites] AJNR Am J Neuroradiol. 2001 May;22(5):818-23 [11337321.001]
  • [Cites] J Clin Oncol. 2006 Mar 10;24(8):1236-45 [16525178.001]
  • [Cites] Neurosurgery. 1991 Mar;28(3):343-8 [2011214.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Feb 1;61(2):374-9 [15667955.001]
  • [Cites] N Engl J Med. 2002 Feb 7;346(6):420-7 [11832530.001]
  • [Cites] Pediatr Hematol Oncol. 1990;7(2):121-8 [1698433.001]
  • (PMID = 17226033.001).
  • [ISSN] 0256-7040
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


14. Ronghe M, Hargrave D, Bartels U, Tabori U, Vaidya S, Chandler C, Kulkarni A, Bouffet E: Vincristine and carboplatin chemotherapy for unresectable and/or recurrent low-grade astrocytoma of the brainstem. Pediatr Blood Cancer; 2010 Sep;55(3):471-7
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vincristine and carboplatin chemotherapy for unresectable and/or recurrent low-grade astrocytoma of the brainstem.
  • BACKGROUND: Radiotherapy remains a widely accepted postoperative treatment modality for unresectable or recurrent low-grade glioma (LGG).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Astrocytoma / drug therapy. Brain Stem. Brain Stem Neoplasms / drug therapy
  • [MeSH-minor] Carboplatin / administration & dosage. Child. Child, Preschool. Disease Progression. Female. Humans. Infant. Male. Neoplasm Recurrence, Local / drug therapy. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Wiley-Liss, Inc.
  • (PMID = 20535831.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; BG3F62OND5 / Carboplatin
  •  go-up   go-down


15. Brassesco MS, Valera ET, Becker AP, Castro-Gamero AM, de Aboim Machado A, Santos AC, Scrideli CA, Oliveira RS, Machado HR, Tone LG: Low-grade astrocytoma in a child with encephalocraniocutaneous lipomatosis. J Neurooncol; 2010 Feb;96(3):437-41
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low-grade astrocytoma in a child with encephalocraniocutaneous lipomatosis.
  • In the present article, we describe a 3-year-old boy with ECCL who developed an extensive and recurring intraventricular low-grade glioma with atypical pathological features and elevated mitotic index.
  • This is the first report of a low-grade astrocytoma occurring in a child with ECCL.
  • [MeSH-major] Astrocytoma / complications. Brain Neoplasms / complications. Lipomatosis / complications. Neurocutaneous Syndromes / complications

  • Genetic Alliance. consumer health - Encephalocraniocutaneous Lipomatosis.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Child Neurol. 2008 Oct;23(10):1186-94 [18952585.001]
  • [Cites] Orphanet J Rare Dis. 2008 Nov 25;3:32 [19032739.001]
  • [Cites] Arch Neurol. 1970 Feb;22(2):144-55 [4902772.001]
  • [Cites] J Med Genet. 1995 Apr;32(4):316-9 [7643367.001]
  • [Cites] Am J Med Genet A. 2007 Dec 15;143A(24):2963-72 [18000987.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Nov;65(11):1049-58 [17086101.001]
  • [Cites] Cancer Genet Cytogenet. 1992 May;60(1):67-73 [1591709.001]
  • [Cites] J Craniomaxillofac Surg. 2005 Aug;33(4):286-9 [15975807.001]
  • [Cites] Med Pediatr Oncol. 2002 Mar;38(3):173-7 [11836716.001]
  • [Cites] Birth Defects Res A Clin Mol Teratol. 2004 Nov;70(11):889-91 [15523665.001]
  • [Cites] Neuropathology. 2009 Jun;29(3):293-8 [18627486.001]
  • [Cites] Cancer Genet Cytogenet. 1994 Aug;76(1):33-5 [8076347.001]
  • [Cites] Cancer Genet Cytogenet. 2001 Nov;131(1):1-12 [11734311.001]
  • [Cites] Brain Dev. 2009 Feb;31(2):104-13 [19028034.001]
  • [Cites] Cancer Genet Cytogenet. 1997 Sep;97(2):125-34 [9283596.001]
  • [Cites] J Cutan Med Surg. 2003 Jan-Feb;7(1):61-5 [12362260.001]
  • [Cites] Am J Med Genet. 1999 Aug 6;85(4):342-5 [10398256.001]
  • [Cites] Cancer Res. 1994 Mar 1;54(5):1324-30 [8118823.001]
  • [Cites] Doc Ophthalmol. 1995;90(1):87-98 [8549249.001]
  • [Cites] Hautarzt. 1993 Jan;44(1):19-22 [8436503.001]
  • [Cites] Cancer Genet Cytogenet. 1998 Jul 15;104(2):157-60 [9666811.001]
  • [Cites] Pediatrics. 1978 Apr;61(4):580-2 [662483.001]
  • [Cites] Am J Med Genet A. 2007 Dec 15;143A(24):2973-80 [18000896.001]
  • [Cites] Clin Exp Dermatol. 2003 Jul;28(4):387-90 [12823300.001]
  • [Cites] Genes Chromosomes Cancer. 1996 Apr;15(4):199-205 [8703845.001]
  • [Cites] J Neuropathol Exp Neurol. 2008 Sep;67(9):878-87 [18716556.001]
  • (PMID = 19652916.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


16. Eroes CA, Zausinger S, Kreth FW, Goldbrunner R, Tonn JC: Intramedullary low grade astrocytoma and ependymoma. Surgical results and predicting factors for clinical outcome. Acta Neurochir (Wien); 2010 Apr;152(4):611-8
Genetic Alliance. consumer health - Ependymoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intramedullary low grade astrocytoma and ependymoma. Surgical results and predicting factors for clinical outcome.
  • RESULTS: Forty-four patients were included (29 ependymomas World Health Organization (WHO) grades I or II, 8 astrocytomas WHO grade I, and 7 astrocytomas WHO grade II).
  • Complete tumor resection was achieved in 79% of ependymomas, 50% of astrocytomas WHO grade I, and 14% of astrocytomas WHO grade II (significantly more often in ependymomas than in astrocytomas, p < 0.05).
  • [MeSH-major] Astrocytoma / surgery. Ependymoma / surgery. Spinal Cord Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20119838.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Austria
  •  go-up   go-down


17. Khan MA, Hashmi S: Low-grade astrocytoma causing calvarial scalloping. Pediatr Neurosurg; 2007;43(2):155-7
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low-grade astrocytoma causing calvarial scalloping.
  • Only 1 case of low-grade astrocytoma causing calvarial erosion has been reported in the literature of the CT era.
  • We report the first case of a low-grade astrocytoma causing calvarial erosion in an adolescent.
  • [MeSH-major] Astrocytoma / diagnosis. Astrocytoma / surgery. Brain Neoplasms / diagnosis. Brain Neoplasms / surgery. Osteolysis / pathology. Osteolysis / surgery. Parietal Lobe / pathology. Parietal Lobe / surgery. Skull / pathology. Skull / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2007 S. Karger AG, Basel.
  • (PMID = 17337932.001).
  • [ISSN] 1016-2291
  • [Journal-full-title] Pediatric neurosurgery
  • [ISO-abbreviation] Pediatr Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


18. Arjona D, Rey JA, Taylor SM: Early genetic changes involved in low-grade astrocytic tumor development. Curr Mol Med; 2006 Sep;6(6):645-50
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early genetic changes involved in low-grade astrocytic tumor development.
  • The most malignant grade of these tumors, glioblastoma multiforme, may arise as a malignant progression from low-grade astrocytoma through anaplastic astrocytoma to secondary GBM, or else it may arise "de novo" as primary GBM.
  • Since malignant transformation is a multistep process, we summarize in this review the earliest genetic changes that seem to be involved in the appearance and development of low-grade astrocytic tumors, where early detection and treatment could be possible.
  • [MeSH-major] Astrocytoma / genetics. Brain Neoplasms / genetics. Glioblastoma / genetics. Models, Genetic. Tumor Suppressor Proteins / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17022734.001).
  • [ISSN] 1566-5240
  • [Journal-full-title] Current molecular medicine
  • [ISO-abbreviation] Curr. Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Tumor Suppressor Proteins
  • [Number-of-references] 80
  •  go-up   go-down


19. Tsai TH, Hwang YF, Hwang SL, Hung CH, Chu CW, Lua BK, Lin CL, Lee KS, Loh JK, Kwan AL, Wang CJ, Huang TY, Howng SL, Lieu AS: Low-grade astrocytoma associated with abscess formation: case report and literature review. Kaohsiung J Med Sci; 2008 May;24(5):262-9
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low-grade astrocytoma associated with abscess formation: case report and literature review.
  • A rare case of low-grade astrocytoma associated with abscess formation occurred in a 52-year-old man presenting with Broca's aphasia.
  • Literature related to brain abscess with brain tumor is reviewed, with an emphasis on abscesses with astrocytoma.
  • [MeSH-major] Astrocytoma / complications. Brain Abscess / etiology. Brain Neoplasms / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18508424.001).
  • [ISSN] 1607-551X
  • [Journal-full-title] The Kaohsiung journal of medical sciences
  • [ISO-abbreviation] Kaohsiung J. Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China (Republic : 1949- )
  •  go-up   go-down


20. Howes TL, Buatti JM, Kirby PA, Carlisle TL, Ryken TC: Radiation induced adult medulloblastoma: a case report. J Neurooncol; 2006 Nov;80(2):191-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Our patient is a 61 year old woman treated with cranial irradiation 15 years previously for a low grade astrocytoma in the left posterior temporal lobe that was recently diagnosed with medulloblastoma in the right cerebellum.
  • [MeSH-minor] Astrocytoma / radiotherapy. Brain Neoplasms / radiotherapy. Craniotomy. Female. Humans. Magnetic Resonance Imaging. Middle Aged. Neurosurgical Procedures. Temporal Lobe / pathology

  • Genetic Alliance. consumer health - Medulloblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurol Neurosurg Psychiatry. 2004 Jun;75 Suppl 2:ii2-11 [15146033.001]
  • [Cites] Tumori. 2003 Jul-Aug;89(4):443-7 [14606653.001]
  • [Cites] Cancer. 1994 Oct 15;74(8):2352-60 [7922986.001]
  • [Cites] J Neurooncol. 1997 Nov;35(2):169-76 [9266455.001]
  • [Cites] Health Phys. 2003 Jul;85(1):43-6 [12852470.001]
  • [Cites] Neurosurgery. 2000 Sep;47(3):623-31; discussion 631-2 [10981749.001]
  • [Cites] Cancer Treat Rev. 1999 Feb;25(1):3-12 [10212586.001]
  • [Cites] J Clin Oncol. 2002 May 1;20(9):2267-76 [11980997.001]
  • [Cites] Surg Neurol. 2003 Jul;60(1):60-7; discussion 67 [12865017.001]
  • [Cites] J Clin Oncol. 2002 May 1;20(9):2223-4 [11980992.001]
  • [Cites] Lancet Neurol. 2003 Jul;2(7):395-403 [12849117.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Oct 1;36(3):549-56 [8948338.001]
  • [Cites] Cancer. 1948 May;1(1):3-29 [18867438.001]
  • (PMID = 16710747.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Fu JB, Parsons HA, Shin KY, Guo Y, Konzen BS, Yadav RR, Smith DW: Comparison of functional outcomes in low- and high-grade astrocytoma rehabilitation inpatients. Am J Phys Med Rehabil; 2010 Mar;89(3):205-12
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of functional outcomes in low- and high-grade astrocytoma rehabilitation inpatients.
  • OBJECTIVES: To compare inpatient rehabilitation outcomes between patients with low- and high-grade astrocytoma.
  • A high-grade (21 of 443 patients) and low-grade astrocytoma (21 of 24 patients) group were matched on three of five criteria in the order of importance: area of brain involvement (divided into left cerebral, right cerebral, midline and/or bilateral cerebral, and infratentorial), single vs. multiple intracranial neurosurgical procedures, age (within 10 yrs), period of rehabilitation admission (within 3 yrs), and sex.
  • The high-grade group had significantly (P < 0.05) higher total gain and longer stay in inpatient rehabilitation (mean +/- standard deviation, 21.7 +/- 10.1 vs. 13.0 +/- 9.3 and 13 +/- 7.1 day vs. 9 +/- 6.2 days, respectively) than did the low-grade astrocytoma group.
  • CONCLUSIONS: Compared with patients with low-grade astrocytoma, patients with high-grade astrocytoma had higher total functional independence measure gain but also longer lengths of stay.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20068429.001).
  • [ISSN] 1537-7385
  • [Journal-full-title] American journal of physical medicine & rehabilitation
  • [ISO-abbreviation] Am J Phys Med Rehabil
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Rondinelli PI, Osório CA, Cohen MP, Novaes PE: Unusual dissemination patterns of low-grade astrocytomas in childhood. Arq Neuropsiquiatr; 2008 Mar;66(1):45-9
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual dissemination patterns of low-grade astrocytomas in childhood.
  • CONTEXT: Low-grade astrocytomas are intracerebral lesions of relatively high frequency in the under-18 pediatric population.
  • We describe here four cases of children with low-grade astrocytoma with aggressive dissemination to the neuroaxis.
  • [MeSH-major] Astrocytoma / secondary. Brain Neoplasms / pathology. Meningeal Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18392413.001).
  • [ISSN] 0004-282X
  • [Journal-full-title] Arquivos de neuro-psiquiatria
  • [ISO-abbreviation] Arq Neuropsiquiatr
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


23. Pan JW, Zhan RY, Tong Y, Zhou YQ, Zhang M: Expression of endothelial nitric oxide synthase and vascular endothelial growth factor in association with neovascularization in human primary astrocytoma. J Zhejiang Univ Sci B; 2005 Jul;6(7):693-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of endothelial nitric oxide synthase and vascular endothelial growth factor in association with neovascularization in human primary astrocytoma.
  • OBJECTIVE: To investigate the relationship between the expression of endothelial nitric oxide synthase (eNOS), vascular endothelial growth factor (VEGF) and angiogenesis in primary astrocytoma.
  • METHODS: Thirty-seven primary astrocytomas and 4 astrocytic hyperplasia samples were collected and divided into three groups according to histological grade.
  • The expression of eNOS or VEGF was light in low-grade astrocytoma and strong in glioblastoma. eNOS expression in astrocytoma was very positively correlated with VEGF. eNOS and VEGF expression in anaplastic astrocytoma was median in contrast to the low grade astrocytoma and glioblastoma.
  • Lower microvascular density was found in low grade astrocytoma than that in higher grade malignant ones.
  • CONCLUSION: This finding suggests that eNOS and VEGF may have cooperative effect in tumor angiogenesis and play an important role in the pathogenesis of primary astrocytoma.
  • [MeSH-major] Astrocytoma / blood supply. Astrocytoma / metabolism. Biomarkers, Tumor / metabolism. Neovascularization, Pathologic / metabolism. Vascular Endothelial Growth Factor A / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2000 Jan 1;95(1):189-97 [10607702.001]
  • [Cites] Cardiovasc Res. 1999 Mar;41(3):773-80 [10435050.001]
  • [Cites] Circ Res. 2000 Apr 28;86(8):892-6 [10785512.001]
  • [Cites] Anal Quant Cytol Histol. 2000 Jun;22(3):267-74 [10872046.001]
  • [Cites] Br J Neurosurg. 2000 Dec;14(6):543-8 [11272032.001]
  • [Cites] Cardiovasc Res. 2001 Feb 16;49(3):568-81 [11166270.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Feb 27;98(5):2604-9 [11226286.001]
  • [Cites] J Neurooncol. 2000 Oct-Nov;50(1-2):139-48 [11245273.001]
  • [Cites] Int J Cancer. 2001 Mar 1;91(5):607-11 [11267968.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2001 Jul;281(1):L278-90 [11404271.001]
  • [Cites] Leukemia. 2001 Sep;15(9):1433-41 [11516104.001]
  • [Cites] Ann Anat. 2003 Dec;185(6):549-54 [14704000.001]
  • [Cites] J Clin Invest. 1998 Jun 1;101(11):2567-78 [9616228.001]
  • [Cites] Acta Neuropathol. 1998 Nov;96(5):453-62 [9829808.001]
  • [Cites] Nature. 1999 Jun 10;399(6736):597-601 [10376602.001]
  • [Cites] Neurosurgery. 1999 Jul;45(1):24-8; discussion 29 [10414562.001]
  • [Cites] Anticancer Res. 2000 Jan-Feb;20(1A):299-304 [10769671.001]
  • (PMID = 15973775.001).
  • [ISSN] 1673-1581
  • [Journal-full-title] Journal of Zhejiang University. Science. B
  • [ISO-abbreviation] J Zhejiang Univ Sci B
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Vascular Endothelial Growth Factor A
  • [Other-IDs] NLM/ PMC1389807
  •  go-up   go-down


24. Aguilar Moliner I, Costa Orvay JA, Juma K, Costa Clara JM, Cruz Martínez O, Pou Fernández J: [Optic pathway astrocytoma: an unusual cause of failure to thrive in infants]. An Pediatr (Barc); 2007 Jun;66(6):622-4
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Optic pathway astrocytoma: an unusual cause of failure to thrive in infants].
  • [Transliterated title] Astrocitoma de vías ópticas: una causa infrecuente de retraso ponderal en el lactante.
  • We report a case of low-grade astrocytoma of the optic pathway in a 2-month-old child whose main symptoms at diagnosis were failure to thrive and anorexia.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17583627.001).
  • [ISSN] 1695-4033
  • [Journal-full-title] Anales de pediatría (Barcelona, Spain : 2003)
  • [ISO-abbreviation] An Pediatr (Barc)
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


25. Zoeller GK, Brathwaite CD, Sandberg DI: Malignant transformation of an optic pathway glioma without prior radiation therapy. J Neurosurg Pediatr; 2010 May;5(5):507-10
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although these tumors can be quite challenging to manage, they are typically low-grade astrocytomas histologically, most commonly pilocytic astrocytomas.
  • The authors report the first case in the English literature of an OPG that transformed from a low-grade astrocytoma, with features most consistent with a pilocytic astrocytoma, to a malignant glioma without any exposure to radiation therapy.

  • Genetic Alliance. consumer health - Glioma.
  • Genetic Alliance. consumer health - Optic pathway glioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20433265.001).
  • [ISSN] 1933-0715
  • [Journal-full-title] Journal of neurosurgery. Pediatrics
  • [ISO-abbreviation] J Neurosurg Pediatr
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


26. Aarsen FK, Paquier PF, Reddingius RE, Streng IC, Arts WF, Evera-Preesman M, Catsman-Berrevoets CE: Functional outcome after low-grade astrocytoma treatment in childhood. Cancer; 2006 Jan 15;106(2):396-402
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Functional outcome after low-grade astrocytoma treatment in childhood.
  • BACKGROUND: The relatively high survival rate of patients with low-grade astrocytoma necessitates increasing attention to physical and psychosocial outcomes.
  • The objective of the current study was to investigate functional outcomes among children who were treated for low-grade or pilocytic astrocytoma in different areas of the brain.
  • CONCLUSIONS: At long-term follow-up, children who had low-grade or pilocytic astrocytomas were found to have poor functional outcomes, depending on tumor site, age, and recurrence.
  • Therefore, the authors suggest a long-term follow-up of children who are treated for low-grade or pilocytic astrocytomas at a young age to detect and subsequently offer support focused on the medical and cognitive impairments as well as on the behavioral and social consequences of their disease.
  • [MeSH-major] Astrocytoma / therapy. Brain Neoplasms / therapy. Disabled Children. Quality of Life

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16353203.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Lee FY, Jan YJ, Wen MC, Li MC, Wang J, Wen-Hsien C: A 32-year-old man with a fourth ventricular mass. Brain Pathol; 2009 Apr;19(2):333-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The features noted are suggestive of a probable better prognosis in this variant of low-grade astrocytoma.
  • [MeSH-major] Astrocytoma / pathology. Cerebral Ventricle Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19291000.001).
  • [ISSN] 1750-3639
  • [Journal-full-title] Brain pathology (Zurich, Switzerland)
  • [ISO-abbreviation] Brain Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein; 0 / S100 Proteins
  •  go-up   go-down


28. Horger M, Fenchel M, Nägele T, Moehle R, Claussen CD, Beschorner R, Ernemann U: Water diffusivity: comparison of primary CNS lymphoma and astrocytic tumor infiltrating the corpus callosum. AJR Am J Roentgenol; 2009 Nov;193(5):1384-7
Hazardous Substances Data Bank. Water .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIALS AND METHODS: Echo-planar diffusion-weighted MR images of 27 patients with glioblastoma multiforme, five patients with low-grade astrocytoma, five patients with gliomatosis cerebri, and nine patients with primary lymphoma infiltrating the corpus callosum were reviewed retrospectively.
  • RESULTS: The mean ADC of glioblastoma multiforme was 1.13 +/- 0.31 (SD) x 10(-3) mm(2)/s, and the mean tumor to corpus callosum ADC ratio was 1.51 +/- 0.46; of low-grade astrocytoma, 1.14 +/- 0.23 x 10(-3) mm(2)/s and 1.54 +/- 0.28; gliomatosis cerebri, 1.01 +/- 0.20 x 10(-3) mm(2)/s and 1.31 +/- 0.36; and lymphoma, 0.71 +/- 0.13 x 10(-3) mm(2)/s and 0.93 +/- 0.19.
  • The difference between the mean tumor to corpus callosum ADC ratio of lymphoma and that of all grades of astrocytoma (1.48 +/- 0.43) was statistically significant (p < 0.001).
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Corpus Callosum / pathology. Diffusion Magnetic Resonance Imaging / methods. Glioblastoma / pathology. Lymphoma / pathology. Water / metabolism

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19843757.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 059QF0KO0R / Water
  •  go-up   go-down


29. Ebinger M, Senf L, Wachowski O, Scheurlen W: No aberrant methylation of neurofibromatosis 1 gene (NF1) promoter in pilocytic astrocytoma in childhood. Pediatr Hematol Oncol; 2005 Jan-Feb;22(1):83-7
Genetic Alliance. consumer health - Pilocytic astrocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] No aberrant methylation of neurofibromatosis 1 gene (NF1) promoter in pilocytic astrocytoma in childhood.
  • With 30-40% of this heterogenous group, low-grade astrocytomas represent the most common subtype.
  • Neurofibromatosis type 1 (NF1) is strongly associated with the development of pilocytic astrocytoma (PA), frequently appearing as optic glioma.
  • To rule out that silencing of NF1 by promoter methylation is restricted to higher-grade astrocytomas, 15 pediatric WHO II degree and IV degree astrocytomas were analyzed: 12 astrocytomas II and 3 glioblastomas displayed no NF1 promoter methylation.
  • The authors conclude that NF1 silencing by methylation plays no role in low-grade astrocytoma.

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • Genetic Alliance. consumer health - Neurofibromatosis type 1.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15770836.001).
  • [ISSN] 0888-0018
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Neurofibromin 1
  •  go-up   go-down


30. Henderson MA, Fakiris AJ, Timmerman RD, Worth RM, Lo SS, Witt TC: Gamma knife stereotactic radiosurgery for low-grade astrocytomas. Stereotact Funct Neurosurg; 2009;87(3):161-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gamma knife stereotactic radiosurgery for low-grade astrocytomas.
  • Patients with low-grade astrocytoma (LGA; 8 pilocytic astrocytomas, 2 subependymal giant cell astrocytomas, 2 fibrillary astrocytomas) were selected for treatment with gamma knife stereotactic radiosurgery (GKSRS) based on having a demarcated appearance on CT or MRI and the possibility of dose sparing of adjacent eloquent structures.
  • GKSRS can provide local control in cases of unresectable or recurrent LGA with a low incidence of side effects in carefully selected patients.
  • [MeSH-major] Astrocytoma / surgery. Brain Neoplasms / surgery. Radiosurgery / methods

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 S. Karger AG, Basel.
  • (PMID = 19321969.001).
  • [ISSN] 1423-0372
  • [Journal-full-title] Stereotactic and functional neurosurgery
  • [ISO-abbreviation] Stereotact Funct Neurosurg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  •  go-up   go-down


31. Nicholson HS, Kretschmar CS, Krailo M, Bernstein M, Kadota R, Fort D, Friedman H, Harris MB, Tedeschi-Blok N, Mazewski C, Sato J, Reaman GH: Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group. Cancer; 2007 Oct 1;110(7):1542-50
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients with a complete (CR) or partial (PR) response or stable disease (SD) could continue temozolomide for up to 12 cycles.
  • PRs occurred in 1 of 23 evaluable patients with high-grade astrocytoma, 1 of 21 with low-grade astrocytoma, and 3 of 25 with medulloblastoma/primitive neuroectodermal tumor (PNET).
  • Notably, 41% of patients with low-grade astrocytoma had SD through 12 courses.
  • The most frequent toxicities were grade 3 or 4 neutropenia (19%) and thrombocytopenia (25%); nonhematologic toxicity was infrequent.
  • CONCLUSIONS: Although overall objective responses were limited, further exploration of temozolomide may be warranted in children with medulloblastoma and other PNETs, or in patients with low-grade astrocytoma, perhaps in a setting of less pretreatment than the patients in the current study, or in the context of multiagent therapy.
  • [MeSH-minor] Administration, Oral. Adolescent. Adult. Astrocytoma / drug therapy. Central Nervous System Neoplasms / drug therapy. Child. Child, Preschool. Drug Administration Schedule. Ependymoma / drug therapy. Female. Humans. Infant. Male. Medulloblastoma / drug therapy. Neuroectodermal Tumors, Primitive / drug therapy. Treatment Outcome


32. Holland H, Koschny T, Ahnert P, Meixensberger J, Koschny R: WHO grade-specific comparative genomic hybridization pattern of astrocytoma - a meta-analysis. Pathol Res Pract; 2010 Oct 15;206(10):663-8
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] WHO grade-specific comparative genomic hybridization pattern of astrocytoma - a meta-analysis.
  • To identify aberration profiles characteristic of World Health Organization (WHO) grade I, II, III, and IV astrocytoma, we performed a meta-analysis of detailed genome wide CGH data of all 467 cases published so far.
  • Low-grade astrocytoma has already demonstrated one characteristic of glioblastoma multiforme, gain of chromosome 7 with a hot spot at 7q32, but without loss of chromosome 10.
  • In anaplastic astrocytoma, a more complex aberration pattern emerges from diffuse genetic imbalances.
  • To quantify the gradual transition from WHO grade II-IV astrocytoma, we calculated the relative increase and decrease in frequency for each detected aberration of the tumor genome.
  • The most pronounced and diverse changes of genetic material occur at the virtual transition from low-grade to anaplastic astrocytoma.
  • Summing up, the expansion of the CGH results to the 850 GTG-band resolution enabled a meta-analysis to visualize WHO grade-specific aberration profiles in astrocytoma.
  • [MeSH-major] Astrocytoma / genetics. Brain Neoplasms / genetics. Chromosome Aberrations. Comparative Genomic Hybridization. Glioblastoma / genetics. World Health Organization

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier GmbH. All rights reserved.
  • (PMID = 20570053.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis
  • [Publication-country] Germany
  •  go-up   go-down


33. Gandelman-Marton R, Segev Y, Theitler J, Rabey JM, Pollak L: Palpitations: could they be neurogenic? A case report. Neurologist; 2006 May;12(3):160-2
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A low-grade astrocytoma was diagnosed in the right frontal lobe.
  • [MeSH-major] Arrhythmias, Cardiac / etiology. Arrhythmias, Cardiac / physiopathology. Astrocytoma / complications. Brain Neoplasms / complications. Frontal Lobe / pathology

  • MedlinePlus Health Information. consumer health - Arrhythmia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16688017.001).
  • [ISSN] 1074-7931
  • [Journal-full-title] The neurologist
  • [ISO-abbreviation] Neurologist
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Dubbink HJ, Taal W, van Marion R, Kros JM, van Heuvel I, Bromberg JE, Zonnenberg BA, Zonnenberg CB, Postma TJ, Gijtenbeek JM, Boogerd W, Groenendijk FH, Smitt PA, Dinjens WN, van den Bent MJ: IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide. Neurology; 2009 Nov 24;73(21):1792-5
SciCrunch. OMIM: Data: Gene Annotation .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide.
  • Patients with high-grade astrocytomas with IDH1 or IDH2 mutations were reported to have a better survival, but it is unknown if this improved survival also holds for low-grade astrocytoma and whether these mutations predict outcome to specific treatment.
  • METHODS: We retrospectively investigated the correlation of IDH1 and IDH2 mutations with overall survival and response to temozolomide in a cohort of patients with dedifferentiated low-grade astrocytomas treated with temozolomide at the time of progression after radiotherapy.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Astrocytoma. Brain Neoplasms. Dacarbazine / analogs & derivatives. Isocitrate Dehydrogenase / genetics. Mutation / genetics

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19933982.001).
  • [ISSN] 1526-632X
  • [Journal-full-title] Neurology
  • [ISO-abbreviation] Neurology
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; EC 1.1.1.41 / Isocitrate Dehydrogenase; EC 1.1.1.41 / isocitrate dehydrogenase 2, human; EC 1.1.1.42. / IDH1 protein, human
  •  go-up   go-down


35. Grahovac G, Tomac D, Lambasa S, Zoric A, Habek M: Cerebellar glioblastomas: pathophysiology, clinical presentation and management. Acta Neurochir (Wien); 2009 Jun;151(6):653-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Most result from de-differentiation from low grade astrocytoma (secondary glioblastoma) or can develop de novo (primary glioblastoma).
  • [MeSH-major] Cerebellar Neoplasms / pathology. Genetic Predisposition to Disease / genetics. Glioblastoma / pathology. Mutation / genetics. Tumor Suppressor Protein p53 / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19319469.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Austria
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


41. Selbekk T, Bang J, Unsgaard G: Strain processing of intraoperative ultrasound images of brain tumours: initial results. Ultrasound Med Biol; 2005 Jan;31(1):45-51
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • During surgery of a low-grade astrocytoma and a metastasis, we acquired ultrasound (US) radiofrequency (RF) data with a hand-held probe at the dura mater.
  • [MeSH-minor] Algorithms. Astrocytoma / surgery. Astrocytoma / ultrasonography. Dura Mater. Elasticity. Humans. Image Processing, Computer-Assisted / methods. Pulsatile Flow. Stress, Mechanical

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15653230.001).
  • [ISSN] 0301-5629
  • [Journal-full-title] Ultrasound in medicine & biology
  • [ISO-abbreviation] Ultrasound Med Biol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


42. Said HM, Hagemann C, Stojic J, Schoemig B, Vince GH, Flentje M, Roosen K, Vordermark D: GAPDH is not regulated in human glioblastoma under hypoxic conditions. BMC Mol Biol; 2007;8:55
Genetic Alliance. consumer health - Glioblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here, we examined (a) the degree of regulation of GAPDH expression in human glioblastoma cells under hypoxic conditions in vitro in comparison to other housekeeping genes like beta-actin, serving as experimental loading controls, (b) the potential use of GAPDH as a target for tumor therapeutic approaches and (c) differences in GAPDH expression between low-grade astrocytomas and glioblastomas, for which modest and severe hypoxia, respectively, have been previously demonstrated.
  • GAPDH and beta-actin expression was comparatively examined in vivo in human low-grade astrocytoma and glioblastoma on both protein and mRNA level, by Western blot and semiquantitative RT-PCR, respectively.
  • In addition, GAPDH expression was similar in patient tumor samples of low-grade astrocytoma and glioblastoma, suggesting a lack of hypoxic regulation in vivo.
  • [MeSH-minor] Actins / genetics. Astrocytoma / genetics. Cell Line, Tumor. Humans. Hypoxia-Inducible Factor 1, alpha Subunit / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochim Biophys Acta. 1999 Oct 28;1447(2-3):208-18 [10542317.001]
  • [Cites] New Horiz. 1995 May;3(2):208-18 [7583162.001]
  • [Cites] Radiother Oncol. 1999 Nov;53(2):127-31 [10665789.001]
  • [Cites] Clin Cancer Res. 2000 Feb;6(2):480-7 [10690527.001]
  • [Cites] Cancer. 2000 Jun 1;88(11):2606-18 [10861440.001]
  • [Cites] Osteoarthritis Cartilage. 2001 May;9(4):357-64 [11399100.001]
  • [Cites] Trends Cell Biol. 2001 Nov;11(11):S32-6 [11684440.001]
  • [Cites] Br J Cancer. 2002 Feb 12;86(4):587-95 [11870542.001]
  • [Cites] Biochim Biophys Acta. 2002 Mar 19;1574(2):152-6 [11955624.001]
  • [Cites] Nature. 2002 Jun 27;417(6892):949-54 [12068308.001]
  • [Cites] Cancer Res. 2002 Aug 1;62(15):4316-24 [12154035.001]
  • [Cites] Biochim Biophys Acta. 2003 Feb 17;1593(2-3):269-76 [12581871.001]
  • [Cites] Biochim Biophys Acta. 2003 Apr 15;1626(1-3):10-8 [12697324.001]
  • [Cites] Radiother Oncol. 2003 Apr;67(1):45-51 [12758239.001]
  • [Cites] J Cell Physiol. 2003 Dec;197(3):312-25 [14566961.001]
  • [Cites] Med Sci Monit. 2004 Aug;10(8):BR250-4 [15277984.001]
  • [Cites] BMC Genet. 2004 Sep 2;5:27 [15341671.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Nov;84(22):7972-6 [2825172.001]
  • [Cites] Anticancer Res. 1988 Jul-Aug;8(4):797-803 [3178168.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Jul;87(14):5273-7 [2164673.001]
  • [Cites] Am J Physiol. 1998 Feb;274(2 Pt 1):C347-55 [9486123.001]
  • [Cites] J Lab Clin Med. 1998 Dec;132(6):456-63 [9851734.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Jun 16;259(3):523-6 [10364451.001]
  • [Cites] Biochim Biophys Acta. 1999 Jul 13;1432(2):159-84 [10407139.001]
  • [Cites] Brain Pathol. 1999 Jul;9(3):469-79 [10416987.001]
  • [Cites] Br J Radiol. 1953 Dec;26(312):609-18 [13106293.001]
  • [Cites] J Cell Mol Med. 2004 Oct-Dec;8(4):423-31 [15601571.001]
  • [Cites] Clin Cancer Res. 2004 Dec 15;10(24):8177-84 [15623592.001]
  • [Cites] J Cereb Blood Flow Metab. 1996 Jan;16(1):77-81 [8530559.001]
  • [Cites] Cell. 1996 Aug 9;86(3):353-64 [8756718.001]
  • [Cites] Cancer Biol Ther. 2004 Nov;3(11):1177-83 [15640620.001]
  • [Cites] Hum Gene Ther. 2005 Jun;16(6):685-98 [15960600.001]
  • [Cites] Biochim Biophys Acta. 2005 Sep 10;1745(2):187-95 [15967517.001]
  • [Cites] Radiother Oncol. 2005 Aug;76(2):200-5 [16024111.001]
  • [Cites] Neuro Oncol. 2005 Oct;7(4):465-75 [16212811.001]
  • [Cites] BMC Mol Biol. 2006;7:15 [16623959.001]
  • [Cites] BMC Mol Biol. 2006;7:27 [16961934.001]
  • [Cites] BMC Mol Biol. 2006;7:30 [16984628.001]
  • [Cites] J Neurooncol. 2007 Jan;81(1):27-38 [16944313.001]
  • [Cites] Radiother Oncol. 2007 Jun;83(3):398-405 [17524506.001]
  • [Cites] Biochem Biophys Res Commun. 1990 Aug 31;171(1):431-8 [2118350.001]
  • [Cites] Biochem Biophys Res Commun. 1993 Sep 15;195(2):1005-10 [8373380.001]
  • [Cites] Prostate. 1993;23(2):123-34 [8104329.001]
  • [Cites] J Biol Chem. 1994 Sep 30;269(39):24446-53 [7929107.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Dec 9;266(1):156-61 [10581182.001]
  • (PMID = 17597534.001).
  • [ISSN] 1471-2199
  • [Journal-full-title] BMC molecular biology
  • [ISO-abbreviation] BMC Mol. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Actins; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; EC 1.2.1.- / Glyceraldehyde-3-Phosphate Dehydrogenases
  • [Other-IDs] NLM/ PMC1919389
  •  go-up   go-down


43. Houben MP, Aben KK, Teepen JL, Schouten-Van Meeteren AY, Tijssen CC, Van Duijn CM, Coebergh JW: Stable incidence of childhood and adult glioma in The Netherlands, 1989-2003. Acta Oncol; 2006;45(3):272-9
Genetic Alliance. consumer health - Glioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In adult astrocytic glioma, a significantly increasing incidence of high-grade astrocytoma was balanced by simultaneous decreases of low-grade astrocytoma, astrocytoma with unknown malignancy grade and glioma of uncertain histology.
  • [MeSH-minor] Adolescent. Adult. Aged. Astrocytoma / epidemiology. Child. Child, Preschool. Cohort Studies. Ependymoma / epidemiology. Europe / epidemiology. Female. Humans. Infant. Infant, Newborn. Male. Middle Aged. Netherlands / epidemiology. Oligodendroglioma / epidemiology. Sex Characteristics. United States / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16644569.001).
  • [ISSN] 0284-186X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Norway
  •  go-up   go-down


44. Pareés I, Alonso J, Rovira A, Martínez E, Montalban X: [Diffuse astrocytoma presenting as an optic-spinal syndrome]. Rev Neurol; 2009 Apr 1-15;48(7):354-6
Genetic Alliance. consumer health - Diffuse Astrocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diffuse astrocytoma presenting as an optic-spinal syndrome].
  • [Transliterated title] Síndrome opticomedular como forma de presentación de un astrocitoma difuso.
  • INTRODUCTION: Spinal cord involvement is a rare presentation of grade II astrocytomas.
  • A patient with an optic-spinal syndrome due to a fibrillary astrocytoma is described.
  • A new MRI with spectroscopy revealed an infiltrative lesion involving the right frontal lobe, optic chiasm, internal capsule, brainstem and cervical spinal cord, which was suggestive of low-grade astrocytoma.
  • Brain biopsy confirmed the diagnosis of diffuse fibrillary astrocytoma.
  • [MeSH-major] Astrocytoma. Demyelinating Diseases. Optic Neuritis. Spinal Cord / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19319816.001).
  • [ISSN] 1576-6578
  • [Journal-full-title] Revista de neurologia
  • [ISO-abbreviation] Rev Neurol
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Oligoclonal Bands
  •  go-up   go-down


45. Kilinçer C, Oztürk L, Hamamcioglu MK, Altunrende E, Cobanoglu S: An upper thoracic spinal cord tumor presenting as hemifacial hyperhidrosis. Surg Neurol; 2007 Oct;68(4):461-3; discussion 463
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The histopathological diagnosis was low-grade astrocytoma.
  • [MeSH-major] Astrocytoma / diagnosis. Hyperhidrosis / etiology. Spinal Cord Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17905075.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


46. Hara A, Saegusa M, Ichinoe M, Okayasu I: Diagnostic and prognostic significance of cyclin A expression in low-grade astrocytomas: comparison with astrogliosis and high-grade tumours. J Clin Pathol; 2008 Mar;61(3):287-92
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic and prognostic significance of cyclin A expression in low-grade astrocytomas: comparison with astrogliosis and high-grade tumours.
  • AIM: Definitive distinction between low-grade astrocytoma and astrogliosis is a long-standing difficulty due to their similar histopathological characteristics.
  • To clarify differences in biological significance, this study focused on various components of the cell cycle machinery and proliferation as key parameters, comparing expression in astrogliosis, as well as low- and high-grade astrocytomas.
  • METHODS: The expression of p16, p21 and p27, and cyclin A, cyclin D1, cyclin E, Rb and Ki-67 was immunohistochemically examined in 40 cases of astrogliosis and 48 cases of low-grade astrocytomas (grade II), as well as 50 high-grade tumours (grades III and IV).
  • RESULTS: Cell proliferation determined by Ki-67 immunoreactivity did not differ between astrogliosis and low-grade tumours.
  • Average labelling indices (LIs) for p16, p21, Rb, cyclin A and cyclin E showed a stepwise increase from astrogliosis, through low- to high-grade astrocytomas, indicating the possibility that over 9%, 6% and 4% of LIs for p16, p21 and cyclin A, respectively, may be useful predictors in the case of the latter, in contrast to significant decrease in p27 LIs.
  • Significantly higher mean LI values for cyclin D1 were also evident in astrogliosis (12.42) as compared with astrocytomas (low grade, 2.26; high grade, 4.60).
  • Positive correlations between LIs for Rb and Ki-67 were observed with astrogliosis and low- but not high-grade tumours.
  • In addition, high cyclin A LI values were independently associated with poor outcome in low-grade tumours.
  • CONCLUSION: These findings provide evidence that expression of cell-cycle-related molecules may be a reliable parameter for differential diagnosis of low-grade astrocytomas and astrogliosis.
  • Moreover, detection of cyclin A appears to be useful for predicting behaviour of low-grade astrocytomas.
  • [MeSH-major] Astrocytoma / genetics. Biomarkers, Tumor. Cyclin A / genetics. Gene Expression Regulation, Neoplastic

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18156430.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cyclin A; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Ki-67 Antigen; 0 / Retinoblastoma Protein; 136601-57-5 / Cyclin D1; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27
  •  go-up   go-down


47. Yokoo H, Tanaka Y, Nobusawa S, Nakazato Y, Ohgaki H: [Analysis of S100beta-v-erbB transgenic rats prone to brain tumors]. Brain Nerve; 2009 Jul;61(7):765-72
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histopathologically, they were classified into four subtypes: glioblastoma-like malignant glioma, anaplastic oligodendroglioma, low-grade oligodendroglioma, and low-grade astrocytoma.
  • [MeSH-major] Astrocytoma / genetics. Brain Neoplasms / genetics. Genetic Predisposition to Disease / genetics. Glioblastoma / genetics. Nerve Growth Factors / genetics. Oligodendroglioma / genetics. Oncogene Proteins v-erbB / genetics. Rats, Transgenic / genetics. S100 Proteins / genetics
  • [MeSH-minor] Animals. Disease Models, Animal. Promoter Regions, Genetic. Rats. Receptor, Epidermal Growth Factor / metabolism. S100 Calcium Binding Protein beta Subunit. Transcription, Genetic

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19618853.001).
  • [ISSN] 1881-6096
  • [Journal-full-title] Brain and nerve = Shinkei kenkyū no shinpo
  • [ISO-abbreviation] Brain Nerve
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Nerve Growth Factors; 0 / Oncogene Proteins v-erbB; 0 / S100 Calcium Binding Protein beta Subunit; 0 / S100 Proteins; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  • [Number-of-references] 22
  •  go-up   go-down


48. Essig M, Rohrer M, Giesel F, Tüttenberg J, Weber MA, Michaely H, Gerigk L, Voth M: Human brain tumor imaging with a protein-binding MR contrast agent: initial experience. Eur Radiol; 2010 Jan;20(1):218-26
Hazardous Substances Data Bank. GADOLINIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • As a result of its significantly higher relaxivity, gadofosveset could, despite its low dose, achieve a sufficient contrast enhancement.
  • In one nonenhancing low grade astrocytoma an enhancing nodule became visible only 5 h after gadofosvesest injection.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Rheumatol Rep. 2006 Apr;8(2):151-7 [16569375.001]
  • [Cites] Radiology. 2005 Sep;236(3):825-33 [16020554.001]
  • [Cites] Nephrol Dial Transplant. 2006 Apr;21(4):1104-8 [16431890.001]
  • [Cites] Semin Oncol. 1994 Apr;21(2):162-71 [8153662.001]
  • [Cites] Radiology. 2006 Dec;241(3):861-72 [17032914.001]
  • [Cites] N Engl J Med. 1991 May 30;324(22):1555-64 [2027359.001]
  • [Cites] Neurosurgery. 2004 Jan;54(1):131-40; discussion 141-2 [14683550.001]
  • [Cites] Curr Opin Investig Drugs. 2004 Sep;5(9):967-76 [15503653.001]
  • [Cites] Top Magn Reson Imaging. 2006 Apr;17(2):89-106 [17198225.001]
  • [Cites] Radiology. 1984 Jul;152(1):71-7 [6729138.001]
  • [Cites] Magn Reson Med. 2003 Mar;49(3):586-90 [12594765.001]
  • [Cites] J Comput Assist Tomogr. 1988 Mar-Apr;12(2):266-74 [3351041.001]
  • [Cites] Invest Radiol. 2005 Nov;40(11):715-24 [16230904.001]
  • [Cites] Invest Radiol. 2001 May;36(5):266-75 [11323514.001]
  • [Cites] Radiology. 2006 Aug;240(2):389-400 [16801373.001]
  • [Cites] Radiology. 1989 Oct;173(1):231-8 [2781014.001]
  • [Cites] Invest Radiol. 2008 Dec;43(12):817-28 [19002053.001]
  • [Cites] Radiology. 2003 Dec;229(3):811-20 [14593194.001]
  • [Cites] Invest Radiol. 2001 Feb;36(2):123-30 [11224761.001]
  • [Cites] AJNR Am J Neuroradiol. 1990 Jul-Aug;11(4):785-91 [2114769.001]
  • [Cites] Magn Reson Imaging Clin N Am. 2008 Nov;16(4):551-60, vii [18926421.001]
  • [Cites] Eur Radiol. 2006 Feb;16 Suppl 2:B15-23 [16802439.001]
  • [Cites] Invest Radiol. 2006 Mar;41(3):229-43 [16481905.001]
  • [Cites] Neuroradiology. 1988;30(2):145-54 [3386808.001]
  • [Cites] Radiology. 1998 May;207(2):539-44 [9577507.001]
  • [Cites] Cancer Treat Rev. 2000 Dec;26(6):449-62 [11139374.001]
  • [Cites] Eur Radiol. 2004 May;14 Suppl 5:M12-8 [15457995.001]
  • (PMID = 19672603.001).
  • [ISSN] 1432-1084
  • [Journal-full-title] European radiology
  • [ISO-abbreviation] Eur Radiol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Blood Proteins; 0 / Contrast Media; 0 / Organometallic Compounds; AU0V1LM3JT / Gadolinium; XM33Q67UVH / gadofosveset trisodium
  •  go-up   go-down


49. Magalhaes A, Godfrey W, Shen Y, Hu J, Smith W: Proton magnetic resonance spectroscopy of brain tumors correlated with pathology. Acad Radiol; 2005 Jan;12(1):51-7
Hazardous Substances Data Bank. CHOLINE CHLORIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In 16 patients with brain astrocytoma of various grades, the pathology grading was correlated with Cho/NAA and Cho/Cr.
  • These values were 6.53 and 3.35 for nine patients with Grade 4 astrocytoma; 1.85 and 1.62 for three patients with Grade 3 astrocytoma; 2.21 and 1.50 for three patients with Grade 2 astrocytoma; and 1.45 and 1.49 for one patient with Grade 1 astrocytoma.
  • In general, high-grade astrocytoma have higher Cho/NAA and Cho/Cr ratios compared with low-grade astrocytoma.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Astrocytoma / diagnosis. Astrocytoma / pathology. Brain / pathology. Choline / analysis. Creatine / analysis. Female. Glioblastoma / diagnosis. Glioblastoma / pathology. Glioma / diagnosis. Glioma / pathology. Gliosarcoma / diagnosis. Gliosarcoma / pathology. Humans. Hydrogen. Image Processing, Computer-Assisted / methods. Male. Middle Aged. Oligodendroglioma / diagnosis. Oligodendroglioma / pathology. Protons

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. HYDROGEN .
  • Hazardous Substances Data Bank. (L)-ASPARTIC ACID .
  • Hazardous Substances Data Bank. CREATINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15691725.001).
  • [ISSN] 1076-6332
  • [Journal-full-title] Academic radiology
  • [ISO-abbreviation] Acad Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protons; 30KYC7MIAI / Aspartic Acid; 7YNJ3PO35Z / Hydrogen; 997-55-7 / N-acetylaspartate; MU72812GK0 / Creatine; N91BDP6H0X / Choline
  •  go-up   go-down


50. Yu JM, Jun ES, Jung JS, Suh SY, Han JY, Kim JY, Kim KW, Jung JS: Role of Wnt5a in the proliferation of human glioblastoma cells. Cancer Lett; 2007 Nov 18;257(2):172-81
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The results of immunohistochemical analyses have revealed that Wnt5a expression was higher in human GBM than in normal brain tissue and low-grade astrocytoma.

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17709179.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein; 0 / Intermediate Filament Proteins; 0 / NES protein, human; 0 / Nerve Tissue Proteins; 0 / Nes protein, mouse; 0 / Nestin; 0 / Proto-Oncogene Proteins; 0 / WNT5A protein, human; 0 / Wnt Proteins
  •  go-up   go-down


51. Eskandary H, Sabba M, Khajehpour F, Eskandari M: Incidental findings in brain computed tomography scans of 3000 head trauma patients. Surg Neurol; 2005 Jun;63(6):550-3; discussion 553
MedlinePlus Health Information. consumer health - Head Injuries.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: In this study we found 30 incidental abnormalities that include 8 cases of tumor: 3 meningioma, 2 craniopharyngioma, 1 oligodendroglioma, 1 low-grade astrocytoma, and 1 medulloblastoma.


52. Lee EJ, Lee SK, Agid R, Bae JM, Keller A, Terbrugge K: Preoperative grading of presumptive low-grade astrocytomas on MR imaging: diagnostic value of minimum apparent diffusion coefficient. AJNR Am J Neuroradiol; 2008 Nov;29(10):1872-7
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative grading of presumptive low-grade astrocytomas on MR imaging: diagnostic value of minimum apparent diffusion coefficient.
  • BACKGROUND AND PURPOSE: Histopathologic grade of glial tumors is inversely correlated with the minimum apparent diffusion coefficient (ADC).
  • We assessed the diagnostic values of minimum ADC for preoperative grading of supratentorial astrocytomas that were diagnosed as low-grade astrocytomas on conventional MR imaging.
  • MATERIALS AND METHODS: Among 118 patients with astrocytomas (WHO grades II-IV), 16 who showed typical MR imaging findings of low-grade supratentorial astrocytomas on conventional MR imaging were included.
  • To assess the relationship between the minimum ADC and tumor grade, we performed the Mann-Whitney U test.
  • A receiver operating characteristic (ROC) analysis was used to determine the cutoff value of the minimum ADC that had the best combination of sensitivity and specificity for distinguishing low- and high-grade astrocytomas.
  • RESULTS: Eight of the 16 patients (50%) were confirmed as having high-grade astrocytomas (WHO grades III and IV), and the other 8 patients were confirmed as having low-grade astrocytomas (WHO grade II).
  • The median minimum ADC of the high-grade astrocytoma (1.035 x 10(-3) mm(2) .
  • sec(-1)) group was significantly lower than that of the low-grade astrocytoma group (1.19 x 10(-3) mm(2) .
  • CONCLUSION: Measuring minimum ADC can provide valuable diagnostic information for the preoperative grading of presumptive low-grade supratentorial astrocytomas.
  • [MeSH-major] Algorithms. Astrocytoma / diagnosis. Brain Neoplasms / diagnosis. Image Interpretation, Computer-Assisted / methods. Magnetic Resonance Imaging / methods

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18719036.001).
  • [ISSN] 1936-959X
  • [Journal-full-title] AJNR. American journal of neuroradiology
  • [ISO-abbreviation] AJNR Am J Neuroradiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. Donato G, Iofrida G, Lavano A, Volpentesta G, Signorelli F, Pallante PL, Berlingieri MT, Pierantoni MG, Palmieri D, Conforti F, Maltese L, Tucci L, Amorosi A, Fusco A: Analysis of UbcH10 expression represents a useful tool for the diagnosis and therapy of astrocytic tumors. Clin Neuropathol; 2008 Jul-Aug;27(4):219-23
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Therefore, to look for possible tools to be used as diagnostic markers in astrocytic neoplasias, we investigated UbcH10 expression in normal brain, gliosis and low-grade and high-grade astrocytic tumors by immunohistochemistry.
  • UbcH10 expression was observed in low-grade astrocytoma and in glioblastoma.
  • Our data indicate a clear correlation between UbcH10 expression and the histological grade of the astrocytic tumors.
  • [MeSH-major] Astrocytoma / diagnosis. Astrocytoma / metabolism. Biomarkers, Tumor / analysis. Brain Neoplasms / diagnosis. Brain Neoplasms / metabolism. Ubiquitin-Conjugating Enzymes / biosynthesis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18666437.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 6.3.2.19 / UBE2C protein, human; EC 6.3.2.19 / Ubiquitin-Conjugating Enzymes
  •  go-up   go-down


54. Zhang K, Li C, Liu Y, Li L, Ma X, Meng X, Feng D: Evaluation of invasiveness of astrocytoma using 1H-magnetic resonance spectroscopy: correlation with expression of matrix metalloproteinase-2. Neuroradiology; 2007 Nov;49(11):913-9
Hazardous Substances Data Bank. CHOLINE CHLORIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of invasiveness of astrocytoma using 1H-magnetic resonance spectroscopy: correlation with expression of matrix metalloproteinase-2.
  • INTRODUCTION: Even low-grade astrocytomas infiltrate the entire brain, a feature that precludes their successful therapy.
  • So to assess the invasive potential of astrocytoma is very important.
  • The aim of this study was determine whether there is a significant correlation between the results of (1)H-magnetic resonance spectroscopy ((1)H-MRS) and tumor invasive potential of astrocytoma, which is reflected by expression of matrix metalloproteinase-2 (MMP-2).
  • According to the World Health Organization classification criteria for central nervous system tumors, there were 16 low-grade astrocytomas (2 pilocytic astrocytomas, 14 grade II astrocytomas) and 25 high-grade astrocytomas (5 anaplastic astrocytomas, 20 glioblastomas).The choline/N-acetylaspartate (Cho/NAA) and choline/creatine (Cho/Cr) ratios were calculated.
  • Of the 41 astrocytomas, 19 (8 low-grade and 11 high-grade) were analyzed immunohistochemically.
  • RESULTS: The Cho/NAA and Cho/Cr ratios of high-grade astrocytoma were both significantly greater than those of low-grade astrocytoma (t = -6.222, P = 0.000; t = -6.533, P = 0.000, respectively).
  • MMP-2 COD values of high-grade astrocytomas were also significantly greater than those of low-grade astrocytomas (t = -5.892, P = 0.000).
  • [MeSH-major] Astrocytoma / metabolism. Astrocytoma / pathology. Brain Neoplasms / metabolism. Brain Neoplasms / pathology. Magnetic Resonance Spectroscopy. Matrix Metalloproteinase 2 / metabolism

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. (L)-ASPARTIC ACID .
  • Hazardous Substances Data Bank. CREATINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Rev Mol Cell Biol. 2002 Mar;3(3):207-14 [11994741.001]
  • [Cites] Int J Dev Neurosci. 1999 Aug-Oct;17(5-6):495-502 [10571411.001]
  • [Cites] Neuroradiology. 2006 May;48(5):312-8 [16552583.001]
  • [Cites] Radiology. 2006 Mar;238(3):958-69 [16424238.001]
  • [Cites] Pharmacol Res. 2002 Aug;46(2):155-63 [12220955.001]
  • [Cites] J Neurooncol. 2000 Dec;50(3):215-26 [11263501.001]
  • [Cites] NMR Biomed. 2004 Feb;17(1):10-20 [15011246.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 22;100(15):8904-9 [12861074.001]
  • [Cites] AJNR Am J Neuroradiol. 1999 Jan;20(1):117-23 [9974066.001]
  • [Cites] Br J Cancer. 2000 Jan;82(1):52-5 [10638966.001]
  • [Cites] J Neurooncol. 2003 Jul;63(3):233-45 [12892229.001]
  • [Cites] Stereotact Funct Neurosurg. 2004;82(2-3):90-7 [15305081.001]
  • [Cites] Am J Pathol. 1998 Aug;153(2):429-37 [9708803.001]
  • [Cites] Neuroradiology. 2002 May;44(5):371-81 [12012120.001]
  • [Cites] AJNR Am J Neuroradiol. 2001 Apr;22(4):604-12 [11290466.001]
  • [Cites] Nat Rev Neurosci. 2001 Jul;2(7):502-11 [11433375.001]
  • [Cites] AJNR Am J Neuroradiol. 2000 Apr;21(4):659-65 [10782774.001]
  • [Cites] AJNR Am J Neuroradiol. 2002 Nov-Dec;23 (10 ):1775-8 [12427638.001]
  • (PMID = 17763847.001).
  • [ISSN] 0028-3940
  • [Journal-full-title] Neuroradiology
  • [ISO-abbreviation] Neuroradiology
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 30KYC7MIAI / Aspartic Acid; 997-55-7 / N-acetylaspartate; EC 3.4.24.24 / Matrix Metalloproteinase 2; MU72812GK0 / Creatine; N91BDP6H0X / Choline
  •  go-up   go-down


55. de Groot JF, Piao Y, Lu L, Fuller GN, Yung WK: Knockdown of GluR1 expression by RNA interference inhibits glioma proliferation. J Neurooncol; 2008 Jun;88(2):121-33
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • High-grade gliomas release excitotoxic concentrations of glutamate which contributes to their malignant phenotype.
  • In a tissue array, there was a statistically significant increase in GluR1 expression in glioblastoma samples compared to anaplastic astrocytoma and low-grade tumors.
  • These results suggest that AMPA receptors are abundantly expressed in high-grade gliomas and gene silencing of the GluR1 AMPA receptor subunit results in abrogation of AMPA-mediated signaling and tumor growth.

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosci. 1999 Dec 15;19(24):10767-77 [10594060.001]
  • [Cites] Nucleic Acids Res. 2003 Nov 1;31(21):e127 [14576327.001]
  • [Cites] Pharmacol Rev. 1999 Mar;51(1):7-61 [10049997.001]
  • [Cites] Expert Rev Anticancer Ther. 2003 Oct;3(5):595-614 [14599084.001]
  • [Cites] J Neurosci. 1993 Sep;13(9):3904-15 [8103555.001]
  • [Cites] Neuron. 2000 Jun;26(3):603-17 [10896157.001]
  • [Cites] Annu Rev Cell Biol. 1991;7:601-32 [1667084.001]
  • [Cites] Neuron. 1994 Jun;12 (6):1207-21 [8011335.001]
  • [Cites] J Biol Chem. 1994 Mar 4;269(9):7030-5 [8120067.001]
  • [Cites] Cancer Metastasis Rev. 2003 Dec;22(4):395-403 [12884914.001]
  • [Cites] J Neurosci. 2005 Aug 3;25(31):7101-10 [16079392.001]
  • [Cites] Mol Cell. 2003 Oct;12(4):889-901 [14580340.001]
  • [Cites] Nat Med. 2002 Sep;8(9):971-8 [12172541.001]
  • [Cites] J Neurooncol. 2001 Feb;51(3):245-64 [11407596.001]
  • [Cites] Brain Pathol. 2002 Jan;12(1):95-107 [11770905.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Dec 4;98(25):14687-92 [11717408.001]
  • [Cites] Trends Neurosci. 2003 Oct;26(10):543-9 [14522147.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jun 19;98(13):7058-61 [11416187.001]
  • [Cites] J Neurosci. 2007 Jul 25;27(30):7987-8001 [17652589.001]
  • [Cites] Nat Methods. 2004 Nov;1(2):163-7 [16144086.001]
  • [Cites] J Neurooncol. 2003 Jan;61(2):151-60 [12622454.001]
  • [Cites] J Cereb Blood Flow Metab. 2007 Aug;27(8):1431-43 [17245419.001]
  • [Cites] J Biol Chem. 1993 Feb 15;268(5):3715-9 [8429046.001]
  • [Cites] Neuron. 1999 Mar;22(3):511-24 [10197531.001]
  • [Cites] Genes Dev. 1995 Sep 15;9(18):2279-91 [7557381.001]
  • [Cites] J Med Chem. 1998 Jul 2;41(14):2513-23 [9651156.001]
  • [Cites] J Neurochem. 2003 Mar;84(6):1288-95 [12614329.001]
  • [Cites] Nature. 1998 Dec 10;396(6711):584-7 [9859994.001]
  • [Cites] Nature. 1999 Jan 7;397(6714):72-6 [9892356.001]
  • [Cites] Biochem Pharmacol. 2002 Oct 15;64(8):1195-200 [12234599.001]
  • [Cites] J Neurosci Res. 1998 Dec 15;54(6):814-9 [9856865.001]
  • [Cites] J Neurooncol. 2000 Mar;47(1):11-22 [10930095.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 May 22;98(11):6372-7 [11331750.001]
  • [Cites] Nat Med. 2001 Sep;7(9):1010-5 [11533703.001]
  • [Cites] J Neurosci. 2005 Feb 16;25(7):1654-63 [15716401.001]
  • [Cites] Cancer Res. 2005 Mar 1;65(5):1934-40 [15753393.001]
  • [Cites] Cancer Res. 1999 Sep 1;59(17):4383-91 [10485487.001]
  • [Cites] J Cereb Blood Flow Metab. 1998 Apr;18(4):396-406 [9538905.001]
  • [Cites] Cancer Res. 2003 Aug 1;63(15):4315-21 [12907597.001]
  • [Cites] Nat Rev Neurosci. 2004 Oct;5(10):771-81 [15378037.001]
  • [Cites] J Biol Chem. 1995 Sep 29;270(39):22783-7 [7559406.001]
  • [Cites] Cancer. 2004 Mar 15;100(6):1110-22 [15022276.001]
  • (PMID = 18317690.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / RNA, Double-Stranded; 0 / RNA, Small Interfering; 0 / Receptors, AMPA; 0 / glutamate receptor ionotropic, AMPA 1
  •  go-up   go-down


56. Jensen RL: Hypoxia in the tumorigenesis of gliomas and as a potential target for therapeutic measures. Neurosurg Focus; 2006;20(4):E24
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The progression of a low-grade astrocytoma to a glioblastoma multiforme may be mediated by hypoxia-induced phenotypic changes and subsequent clonal selection of cells that overexpress hypoxia-responsive molecules, such as HIF-1.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16709030.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / HIF1A protein, human; 0 / Hypoxia-Inducible Factor 1, alpha Subunit
  • [Number-of-references] 166
  •  go-up   go-down


57. Gheri CF, Buccoliero AM, Pansini G, Castiglione F, Garbini F, Moncini D, Maccari C, Mennonna P, Pellicanò G, Ammannati F, Taddei GL: Lipoastrocytoma: Case report and review of the literature. Neuropathology; 2010 Oct;30(5):553-8
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report the case of an astrocytoma involving the upper part of the cerebellar-pontine angle and the right portion of the clivus starting from the brainstem with a diffuse lipomatous component in a 39 year-old man.
  • Histologically the tumor showed the classical histology of low-grade astrocytoma and a portion of the lesion was composed of lipid-laden cells.
  • Ki-67/Mib-1 labeling index was low (2%).
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Lipomatosis / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 Japanese Society of Neuropathology.
  • (PMID = 20113404.001).
  • [ISSN] 1440-1789
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Australia
  • [Keywords] NOTNLM ; lipid vacuole / lipoastrocytoma / lipomatous / low grade astrocytoma
  •  go-up   go-down


58. Yao Y, Kubota T, Takeuchi H, Sato K: Prognostic significance of microvessel density determined by an anti-CD105/endoglin monoclonal antibody in astrocytic tumors: comparison with an anti-CD31 monoclonal antibody. Neuropathology; 2005 Sep;25(3):201-6
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The mean CD31-MVD and CD105-MVD was 36.7 and 24.8 for low-grade astrocytoma (LGA), 48.0 and 42.7 for anaplastic astrocytoma, 55.3 and 51.9 for glioblastoma multiforme (GBM), respectively.
  • Whereas the MST of patients with higher CD31-MVD tumors seemed to be shorter than that of lower CD31-MVD patients within each tumor grade, the differences were not statistically significant.
  • [MeSH-major] Antibodies, Monoclonal. Astrocytoma / blood supply. Biomarkers, Tumor / analysis. Brain Neoplasms / mortality. Neovascularization, Pathologic / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16193836.001).
  • [ISSN] 0919-6544
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD; 0 / Antigens, CD31; 0 / Biomarkers, Tumor; 0 / ENG protein, human; 0 / Receptors, Cell Surface; 0 / Vascular Cell Adhesion Molecule-1; 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


59. Pérez-Gómez JL, Rodríguez-Alvarez CA, Marhx-Bracho A, Rueda-Franco F: Stereotactic biopsy for brainstem tumors in pediatric patients. Childs Nerv Syst; 2010 Jan;26(1):29-34
MedlinePlus Health Information. consumer health - Biopsy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The histopathology was anaplastic astrocytoma (30%), followed by fibrillary and pilocytic types (25% each), low-grade astrocytoma (5%), high-grade astrocytoma (5%), and normal tissue (10%).
  • CONCLUSIONS: Stereotactic biopsy done for clarifiying a diagnostic imaging in brainstem tumors is important in obtaining a definitive diagnosis with a low rate of complications.
  • [MeSH-major] Astrocytoma / pathology. Biopsy / methods. Brain Stem / pathology. Brain Stem Neoplasms / pathology. Stereotaxic Techniques

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 2006 Feb;104(2 Suppl):108-14 [16506498.001]
  • [Cites] Acta Neurochir (Wien). 1985;76(1-2):12-7 [4003123.001]
  • [Cites] Childs Nerv Syst. 2006 Jan;22(1):1-2 [16311768.001]
  • [Cites] Cancer. 1980 Jun 1;45(11):2787-92 [7379009.001]
  • [Cites] J Neurosurg. 1989 Sep;71(3):466-7 [2671296.001]
  • [Cites] Acta Neurochir (Wien). 1998;140(9):899-903 [9842426.001]
  • [Cites] J Neurooncol. 1988 Dec;6(4):309-17 [3221258.001]
  • [Cites] Childs Nerv Syst. 2007 Mar;23(3):315-9 [17058082.001]
  • [Cites] Childs Nerv Syst. 2003 Jun;19(5-6):305-10 [12732939.001]
  • [Cites] Childs Nerv Syst. 2004 Mar;20(3):143-53 [14669023.001]
  • [Cites] Acta Neurochir Suppl (Wien). 1989;46:86-9 [2672719.001]
  • [Cites] Surg Neurol. 1995 Jun;43(6):558-62 [7482234.001]
  • [Cites] J Neurosurg. 2000 Dec;93(6):951-7 [11117867.001]
  • [Cites] Neurosurgery. 1983 Mar;12 (3):298-302 [6302553.001]
  • [Cites] Surg Neurol. 1995 Jun;43(6):563-7; discussion 567-8 [7482235.001]
  • [Cites] Surg Neurol. 2003 Oct;60(4):311-20; discussion 320 [14505847.001]
  • [Cites] J Neurosurg. 1986 Jan;64(1):11-5 [3941334.001]
  • [Cites] Acta Neurochir (Wien). 1992;116(2-4):164-70 [1502952.001]
  • [Cites] Surg Neurol. 1987 Aug;28(2):100-4 [3299823.001]
  • [Cites] J Neurosurg. 1989 Feb;70(2):195-200 [2643686.001]
  • [Cites] Neurosurgery. 1987 Mar;20(3):439-44 [3574621.001]
  • [Cites] Neurosurgery. 1980 Sep;7(3):243-8 [7207742.001]
  • [Cites] Arch Dis Child. 1999 Jun;80(6):558-64 [10332008.001]
  • (PMID = 19784659.001).
  • [ISSN] 1433-0350
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


60. Gu J, Zhang C, Chen R, Pan J, Wang Y, Ming M, Gui W, Wang D: Clinical implications and prognostic value of EMMPRIN/CD147 and MMP2 expression in pediatric gliomas. Eur J Pediatr; 2009 Jun;168(6):705-10
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The intensively positive expression rates of EMMPRIN (22/27) and MMP2 (21/27) in anaplastic astrocytoma and glioblastoma tissues were significantly higher than those in normal brain and low-grade astrocytoma tissues (2/28 and (1/2)8, respectively).
  • The positive expression of EMMPRIN and MMP2 was associated with higher grade gliomas.
  • [MeSH-major] Antigens, CD147 / metabolism. Astrocytoma / metabolism. Brain Neoplasms / metabolism. Brain Neoplasms / mortality. Matrix Metalloproteinase 2 / metabolism
  • [MeSH-minor] Child. Child, Preschool. Disease Progression. Female. Humans. Immunohistochemistry. Infant. Male. Prognosis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pathol. 2002 Apr;160(4):1215-21 [11943706.001]
  • [Cites] Brain Pathol. 1993 Jul;3(3):255-68 [8293185.001]
  • [Cites] Int J Cancer. 2003 Feb 20;103(5):647-51 [12494473.001]
  • [Cites] Am J Pathol. 1999 Feb;154(2):417-28 [10027400.001]
  • [Cites] Cancer Res. 2004 Feb 15;64(4):1229-32 [14983875.001]
  • [Cites] Am J Pathol. 2001 Jun;158(6):1921-8 [11395366.001]
  • [Cites] Brain Pathol. 2007 Jul;17(3):276-81 [17465990.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):2276-81 [11280798.001]
  • [Cites] Pathol Int. 2006 Jul;56(7):359-67 [16792544.001]
  • [Cites] Rev Recent Clin Trials. 2006 May;1(2):119-31 [18473963.001]
  • [Cites] Int J Cancer. 2002 May 10;99(2):157-66 [11979428.001]
  • [Cites] Mol Cancer Res. 2005 Oct;3(10):541-51 [16254188.001]
  • [Cites] Cancer Gene Ther. 2003 Nov;10(11):823-32 [14605668.001]
  • [Cites] Cancer. 2004 Nov 1;101(9):1994-2000 [15372476.001]
  • [Cites] Br J Cancer. 1996 Jun;73(11):1401-8 [8645587.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):3193-9 [15833850.001]
  • [Cites] Int J Cancer. 2003 Sep 20;106(5):745-51 [12866035.001]
  • [Cites] Cancer Immunol Immunother. 2008 Sep;57(9):1367-79 [18273614.001]
  • [Cites] Am J Pathol. 1996 Jul;149(1):273-82 [8686751.001]
  • [Cites] Cancer Res. 2007 May 1;67(9):4088-97 [17483319.001]
  • [Cites] Am J Pathol. 2005 Jan;166(1):209-19 [15632013.001]
  • [Cites] Oncogene. 2007 Aug 9;26(36):5229-37 [17325663.001]
  • [Cites] Int J Cancer. 2006 Oct 15;119(8):1800-10 [16721788.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10 ):987-96 [15758009.001]
  • (PMID = 18795327.001).
  • [ISSN] 1432-1076
  • [Journal-full-title] European journal of pediatrics
  • [ISO-abbreviation] Eur. J. Pediatr.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / BSG protein, human; 136894-56-9 / Antigens, CD147; EC 3.4.24.24 / Matrix Metalloproteinase 2
  •  go-up   go-down


61. Akiyama H, Nakamizo S, Kawamura A, Nagashima T, Takeda H, Hasegawa D, Kosaka Y, Yoshida M: [Management of chiasmatic-hypothalamic gliomas in children: report of nine pediatric cases]. No Shinkei Geka; 2007 Nov;35(11):1079-85
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pathological examination revealed pilocytic astrocytomas in 7 patients, low grade astrocytoma in 1 and anaplastic astrocytoma in 1.

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18044225.001).
  • [ISSN] 0301-2603
  • [Journal-full-title] No shinkei geka. Neurological surgery
  • [ISO-abbreviation] No Shinkei Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


62. McNatt SA, Gonzalez-Gomez I, Nelson MD, McComb JG: Synchronous multicentric pleomorphic xanthoastrocytoma: case report. Neurosurgery; 2005 Jul;57(1):E191; discussion E191
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE AND IMPORTANCE: Pleomorphic xanthoastrocytoma (PXA) is a rare, low-grade astrocytoma of adolescence.
  • Three years after treatment, the patient remains neurologically nonfocal and shows no evidence of disease progression.
  • [MeSH-major] Astrocytoma. Brain Neoplasms. Neoplasms, Multiple Primary

  • Genetic Alliance. consumer health - Pleomorphic xanthoastrocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15987556.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


63. Fuller GN, Mircean C, Tabus I, Taylor E, Sawaya R, Bruner JM, Shmulevich I, Zhang W: Molecular voting for glioma classification reflecting heterogeneity in the continuum of cancer progression. Oncol Rep; 2005 Sep;14(3):651-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular voting for glioma classification reflecting heterogeneity in the continuum of cancer progression.
  • Gliomas, the most common brain tumors, are generally categorized into two lineages (astrocytic and oligodendrocytic) and further classified as low-grade (astrocytoma and oligodendroglioma), mid-grade (anaplastic astrocytoma and anaplastic oligodendroglioma), and high-grade (glioblastoma multiforme) based on morphological features.
  • A strict classification scheme has limitations because a specific glioma can be at any stage of the continuum of cancer progression and may contain mixed features.
  • Thus, a more comprehensive classification based on molecular signatures may reflect the biological nature of specific tumors more accurately.
  • In this study, we used microarray technology to profile the gene expression of 49 human brain tumors and applied the k-nearest neighbor algorithm for classification.
  • We first trained the classification gene set with 19 of the most typical glioma cases and selected a set of genes that provide the lowest cross-validation classification error with k=5.
  • [MeSH-major] Brain Neoplasms / classification. Gene Expression Profiling. Glioma / classification. Oligonucleotide Array Sequence Analysis / methods
  • [MeSH-minor] Algorithms. Disease Progression. Gene Expression Regulation, Neoplastic / genetics. Genetic Heterogeneity

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16077969.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Greece
  •  go-up   go-down


64. Rathi KR, Radotra BD, Khosla VK: Proliferative index in astrocytic tumours. Indian J Pathol Microbiol; 2007 Oct;50(4):754-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although internationally accepted WHO grading system of CNS tumours is based on histological features of H&E stained sections, yet there are cases where differentiation between grade II and grade III is difficult particularly when the biopsy is small.
  • Formalin-fixed paraffin-embedded surgical specimens from 90 cases of astrocytic tumours, 30 each of low-grade astrocytoma (grade II), anaplastic astrocytoma (grade III), and glioblastoma multiforme (grade IV), were immunostained by standard indirect immunoperoxidase technique using MIB-1 monoclonal antibody.
  • The mean MIB-1 LI values of astrocytomas, anaplastic astrocytomas and glioblastomas were 1.75 +/- 1.5%, 8.74 +/- 6.2%, and 20.54 +/- 12.2% respectively and there was statistically significant difference between grade II and III (Unpaired "t" test, T value 5.907, p value < 0.001) and grade III and grade IV (T value 4.734, p value < 0.001).
  • The statistical analysis also revealed that the mean MIB-1 LI increased with histological grade of malignancy (One way ANOVA test, p value < 0.001).
  • [MeSH-major] Astrocytoma / classification. Astrocytoma / pathology. Cell Proliferation. Glioblastoma / classification. Glioblastoma / pathology. Severity of Illness Index
  • [MeSH-minor] Brain Neoplasms / chemistry. Brain Neoplasms / classification. Brain Neoplasms / pathology. Flavivirus. Humans. Immunohistochemistry / methods. Ubiquitin-Protein Ligases / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18306542.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] EC 6.3.2.19 / MIB1 ligase, human; EC 6.3.2.19 / Ubiquitin-Protein Ligases
  •  go-up   go-down


65. Büyükpamukçu M, Varan A, Yazici N, Akalan N, Söylemezoğlu F, Zorlu F, Akyüz C, Kutluk MT: Second malignant neoplasms following the treatment of brain tumors in children. J Child Neurol; 2006 May;21(5):433-6
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The second malignant neoplasms were diagnosed as non-Hodgkin lymphoma, myelodysplastic syndrome, basal cell carcinoma, malignant melanoma, Kaposi sarcoma, and high-grade neuroectodermal tumor.
  • The initial diagnoses were ependymoblastoma in one, medulloblastoma in three, and low-grade astrocytoma in two patients.
  • The patients who developed non-Hodgkin lymphoma and myelodysplastic syndrome died of progressive disease.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16901454.001).
  • [ISSN] 0883-0738
  • [Journal-full-title] Journal of child neurology
  • [ISO-abbreviation] J. Child Neurol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


66. Xie D, Zeng YX, Wang HJ, Tai LS, Wen JM, Tao Y, Ma NF, Hu L, Sham JS, Guan XY: Amplification and overexpression of epidermal growth factor receptor gene in glioblastomas of Chinese patients correlates with patient's age but not with tumor's clinicopathological pathway. Acta Neuropathol; 2005 Nov;110(5):481-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary (de novo) GBM most often occurs in older individuals, and is characterized by the overexpression/amplification of epidermal growth factor receptor gene (EGFR), whereas secondary GBM, which progresses from a low-grade astrocytoma, often affects younger individuals and frequently contains the TP53 mutation.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • MedlinePlus Health Information. consumer health - Seniors' Health.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16151725.001).
  • [ISSN] 0001-6322
  • [Journal-full-title] Acta neuropathologica
  • [ISO-abbreviation] Acta Neuropathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Tumor Suppressor Protein p53; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


67. Marcus KJ, Goumnerova L, Billett AL, Lavally B, Scott RM, Bishop K, Xu R, Young Poussaint T, Kieran M, Kooy H, Pomeroy SL, Tarbell NJ: Stereotactic radiotherapy for localized low-grade gliomas in children: final results of a prospective trial. Int J Radiat Oncol Biol Phys; 2005 Feb 1;61(2):374-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stereotactic radiotherapy for localized low-grade gliomas in children: final results of a prospective trial.
  • Of the 81 patients, 50 had low-grade astrocytoma, 23 had residual or recurrent craniopharyngioma, 4 had posterior fossa ependymoma, and 4 had other histologic types.
  • This report focused on the patients with low-grade gliomas only.
  • The indications for treatment of patients with low-grade gliomas were progression during or after chemotherapy or progression after surgery alone.
  • Two of the patients with local progression had pathologic progression to anaplastic astrocytoma 3 and 7 years after initial SRT.
  • Six patients died, three of dissemination, two of progression to higher grade tumors, and one of a secondary radiation-induced tumor.
  • CONCLUSION: Stereotactic radiotherapy provides excellent local control for children with small, localized low-grade glial tumors.
  • [MeSH-major] Astrocytoma / surgery. Brain Neoplasms / surgery. Radiosurgery
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Confidence Intervals. Disease Progression. Disease-Free Survival. Female. Humans. Male. Neoplasm Recurrence, Local / drug therapy. Prospective Studies. Radiotherapy Dosage

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15667955.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


68. Jaing TH, Lin KL, Tsay PK, Hsueh C, Hung PC, Wu CT, Tseng CK: Treatment of optic pathway hypothalamic gliomas in childhood: experience with 18 consecutive cases. J Pediatr Hematol Oncol; 2008 Mar;30(3):222-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histologic studies showed low-grade astrocytoma (WHO grade I or II) in 16 cases, anaplastic astrocytoma in 1, and oligoastrocytoma (WHO grade III) in 1.
  • Because progression of these tumors is slow and associated with endocrinopathy, we recommend chemotherapy as a primary treatment of OPHG if the disease progresses.
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Disease Progression. Female. Follow-Up Studies. Humans. Infant. Magnetic Resonance Imaging. Male. Predictive Value of Tests. Retrospective Studies. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18376285.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


69. Torii K, Tsuyuguchi N, Kawabe J, Sunada I, Hara M, Shiomi S: Correlation of amino-acid uptake using methionine PET and histological classifications in various gliomas. Ann Nucl Med; 2005 Dec;19(8):677-83
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumors included diffuse astrocytoma, anaplastic astrocytoma, glioblastoma, ependymoma, oligodendroglioma, medulloblastoma, dysembryoplastic neuroepithelial tumor, choroid plexus papilloma, central neurocytoma, optic glioma, gliomatosis cerebri, pleomorphic xanthoastrocytoma, and ganglioglioma.
  • Ki-67LI differed significantly between the high-grade group and low-grade group at T/N levels between 1.5 and 1.8 on analysis using tumor proliferative potential (p = 0.019-0.031).
  • The prognosis differed significantly between the high-grade and low-grade groups when T/N was in the range of 1.6-1.8 (p = 0.028-0.032).
  • The cut-off level of T/N ratio for distinction between high-grade and low-grade astrocytoma appears to lie between 1.5 and 1.6.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • Hazardous Substances Data Bank. (L)-Methionine .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16444993.001).
  • [ISSN] 0914-7187
  • [Journal-full-title] Annals of nuclear medicine
  • [ISO-abbreviation] Ann Nucl Med
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 58576-49-1 / carbon-11 methionine; AE28F7PNPL / Methionine
  •  go-up   go-down


70. Tang J, Flomenberg P, Harshyne L, Kenyon L, Andrews DW: Glioblastoma patients exhibit circulating tumor-specific CD8+ T cells. Clin Cancer Res; 2005 Jul 15;11(14):5292-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • EXPERIMENTAL DESIGN: Peripheral blood mononuclear cells (PBMC) and tumor cells were obtained from nine patients with newly diagnosed brain tumors: five glioblastoma multiforme, two oligodendroglioma, one ependymoma, and one astrocytoma.
  • Additionally, all glioblastoma multiforme patients responded to autologous dendritic cells loaded with U118 lysate but not with low-grade astrocytoma cell lysates.

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16033848.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / HLA Antigens; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


71. Roujeau T, Machado G, Garnett MR, Miquel C, Puget S, Geoerger B, Grill J, Boddaert N, Di Rocco F, Zerah M, Sainte-Rose C: Stereotactic biopsy of diffuse pontine lesions in children. J Neurosurg; 2007 Jul;107(1 Suppl):1-4
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECT: Empirical radiotherapy is the current treatment for children with diffuse pontine lesions that have imaging characteristics of an infiltrative malignant astrocytoma.
  • A histological diagnosis was made in all 24 patients as follows: 22 had a malignant infiltrative astrocytoma, one had a low-grade astrocytoma, and one had a pilocytic astrocytoma.
  • A nonmalignant tumor was identified in two of the 24 patients in whom the imaging findings were characteristic of a malignant infiltrative astrocytoma.
  • [MeSH-major] Astrocytoma / pathology. Biopsy, Needle. Brain Stem Neoplasms / pathology. Magnetic Resonance Imaging. Pons / pathology. Stereotaxic Techniques

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Neurosurg Pediatr. 2008 May;1(5):423; author reply 424-5 [18447684.001]
  • [CommentIn] J Neurosurg Pediatr. 2008 May;1(5):423-4; author reply 424-5 [18536100.001]
  • [CommentIn] J Neurosurg Pediatr. 2008 May;1(5):424; author reply 424-5 [18533336.001]
  • (PMID = 17647306.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


72. Gupta RK, Hasan KM, Mishra AM, Jha D, Husain M, Prasad KN, Narayana PA: High fractional anisotropy in brain abscesses versus other cystic intracranial lesions. AJNR Am J Neuroradiol; 2005 May;26(5):1107-14
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We performed diffusion tensor imaging (DTI) in 12 patients with cystic intracranial lesions (pyogenic abscess, n = 5; cysticercus cysts, n = 2; and low-grade astrocytoma, n = 5).
  • The cystic tumors and neurocysticercosis showed very high D(av) = (2.806 +/- 0.25, 2.654 +/- 0.35)x 10(-3) mm(2)/s, with low FA = (0.108 +/- 0.037, 0.08 +/- 0.01), respectively.

  • MedlinePlus Health Information. consumer health - Brain Diseases.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15891168.001).
  • [ISSN] 0195-6108
  • [Journal-full-title] AJNR. American journal of neuroradiology
  • [ISO-abbreviation] AJNR Am J Neuroradiol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


73. Bentsion DL, Gvozdev PB, Sakovich VP, Fialko NV, Kolotvinov VS, Baiankina SN: [The first experience in interstitial brachytherapy for primary and metastatic tumors of the brain]. Zh Vopr Neirokhir Im N N Burdenko; 2006 Jan-Mar;(1):18-21; discussion 21
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The histostructural distribution was as follows: low-grade astrocytoma (grade II according to the WHO classification) in 2 patients, anaplastic astrocytoma (AA) in 3, glioblastoma multiforme (GBM) in 5.
  • Six patients died from progressive disease.
  • All patients with low-grade astrocytoma and one patient with anaplastic astrocytoma were alive at month 24 after treatment termination.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16739930.001).
  • [ISSN] 0042-8817
  • [Journal-full-title] Zhurnal voprosy neĭrokhirurgii imeni N. N. Burdenko
  • [ISO-abbreviation] Zh Vopr Neirokhir Im N N Burdenko
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


74. Said HM, Hagemann C, Staab A, Stojic J, Kühnel S, Vince GH, Flentje M, Roosen K, Vordermark D: Expression patterns of the hypoxia-related genes osteopontin, CA9, erythropoietin, VEGF and HIF-1alpha in human glioma in vitro and in vivo. Radiother Oncol; 2007 Jun;83(3):398-405
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND PURPOSE: To identify molecular markers of tumor hypoxia and potential therapeutic targets in glioblastoma (GBM), we investigated the hypoxia-related expression of osteopontin (OPN), carbonic anhydrase 9 (CA9), erythropoietin (EPO), vascular endothelial growth factor (VEGF) and hypoxia-inducible factor-1alpha (HIF-1alpha) in vitro in human GBM cell lines and in vivo in human tumor samples of GBM, compared to low-grade astrocytoma (LGA).

  • Genetic Alliance. consumer health - Glioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17524506.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / HIF1A protein, human; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / RNA, Messenger; 0 / Vascular Endothelial Growth Factor A; 106441-73-0 / Osteopontin; EC 4.2.1.1 / CA9 protein, human; EC 4.2.1.1 / Carbonic Anhydrases
  •  go-up   go-down


75. Rodriguez FJ, Perry A, Gutmann DH, O'Neill BP, Leonard J, Bryant S, Giannini C: Gliomas in neurofibromatosis type 1: a clinicopathologic study of 100 patients. J Neuropathol Exp Neurol; 2008 Mar;67(3):240-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Most tumors were typical pilocytic astrocytoma (PA) (49%) or diffusely infiltrating astrocytoma (DA) (27%) that included World Health Organization Grades II (5%), III (15%), and IV (7%); others were designated as low-grade astrocytoma, subtype indeterminate (LGSI; 17%).
  • The tumors in 24 cases arose in the optic pathways and included PA (n = 14), LGSI (n = 4), DA (n = 4), pilomyxoid astrocytoma (n = 1), and ganglioglioma (n = 1).

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • Genetic Alliance. consumer health - Neurofibromatosis type 1.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurosurgery. 1979 Jun;4(6):524-8 [113690.001]
  • [Cites] Arch Neurol. 1966 May;14(5):467-75 [4957904.001]
  • [Cites] J Neurosurg. 1987 Jan;66(1):58-71 [3097276.001]
  • [Cites] Neuroradiology. 1991;33(4):357-9 [1922756.001]
  • [Cites] JAMA. 1997 Jul 2;278(1):51-7 [9207339.001]
  • [Cites] J Neuropathol Exp Neurol. 1999 Oct;58(10):1061-8 [10515229.001]
  • [Cites] Pediatr Blood Cancer. 2006 Mar;46(3):377-80 [15800886.001]
  • [Cites] Neurology. 2006 Oct 24;67(8):1509-12 [17060590.001]
  • [Cites] J AAPOS. 2006 Dec;10(6):534-9 [17189147.001]
  • [Cites] Ann Neurol. 2007 Mar;61(3):189-98 [17387725.001]
  • [Cites] Hum Mol Genet. 2007 May 1;16(9):1098-112 [17400655.001]
  • [Cites] Cancer Res. 2007 Sep 15;67(18):8588-95 [17875698.001]
  • [Cites] Acta Neuropathol. 2000 May;99(5):563-70 [10805102.001]
  • [Cites] Childs Nerv Syst. 2000 Jul;16(7):417-20 [10958550.001]
  • [Cites] Arch Ophthalmol. 2001 Apr;119(4):516-29 [11296017.001]
  • [Cites] Childs Nerv Syst. 2002 Feb;18(1-2):43-7 [11935243.001]
  • [Cites] Neurology. 2002 Sep 10;59(5):759-61 [12221173.001]
  • [Cites] Brain. 2003 Jan;126(Pt 1):152-60 [12477702.001]
  • [Cites] Am J Med Genet A. 2003 Oct 1;122A(2):95-9 [12955759.001]
  • [Cites] Ophthalmology. 2004 Mar;111(3):568-77 [15019338.001]
  • [Cites] J Clin Neurosci. 2004 Sep;11(7):745-7 [15337138.001]
  • [Cites] Pathol Annu. 1985;20 Pt 1:331-58 [3921930.001]
  • (PMID = 18344915.001).
  • [ISSN] 0022-3069
  • [Journal-full-title] Journal of neuropathology and experimental neurology
  • [ISO-abbreviation] J. Neuropathol. Exp. Neurol.
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / T32 NS007494; United States / NINDS NIH HHS / NS / T32 NS07494-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ NIHMS396162; NLM/ PMC3417064
  •  go-up   go-down


76. Burgoyne AM, Palomo JM, Phillips-Mason PJ, Burden-Gulley SM, Major DL, Zaremba A, Robinson S, Sloan AE, Vogelbaum MA, Miller RH, Brady-Kalnay SM: PTPmu suppresses glioma cell migration and dispersal. Neuro Oncol; 2009 Dec;11(6):767-78
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Glioblastomas (GBMs) are the highest grade of primary brain tumors with astrocytic similarity and are characterized by marked dispersal of tumor cells.
  • PTPmu expression was examined in human GBM, low-grade astrocytoma, and normal brain tissue.
  • These studies revealed a striking loss of PTPmu protein expression in highly dispersive GBMs compared to less dispersive low-grade astrocytomas and normal brain.

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dev Biol. 2004 Jan 1;265(1):23-32 [14697350.001]
  • [Cites] Mol Cell Biol. 1994 Jan;14(1):1-9 [8264577.001]
  • [Cites] Cancer Lett. 2004 Apr 8;206(2):181-91 [15013523.001]
  • [Cites] Mol Cell Biochem. 1993 Nov;127-128:131-41 [7935345.001]
  • [Cites] J Biol Chem. 1994 Nov 11;269(45):28472-7 [7961788.001]
  • [Cites] J Cell Biol. 1995 Oct;131(1):251-60 [7559782.001]
  • [Cites] J Biol Chem. 1997 Mar 14;272(11):7264-77 [9054423.001]
  • [Cites] J Cell Biol. 1998 Apr 6;141(1):287-96 [9531566.001]
  • [Cites] J Virol. 1998 Nov;72(11):8463-71 [9765382.001]
  • [Cites] J Cell Biol. 1999 Mar 22;144(6):1323-36 [10087273.001]
  • [Cites] J Neurooncol. 2004 Nov;70(2):217-28 [15674479.001]
  • [Cites] J Biol Chem. 2005 Nov 11;280(45):37516-25 [16150730.001]
  • [Cites] J Biol Chem. 2006 Feb 24;281(8):4903-10 [16380380.001]
  • [Cites] J Neurochem. 2006 Sep;98(5):1497-506 [16923162.001]
  • [Cites] Nat Rev Mol Cell Biol. 2006 Nov;7(11):833-46 [17057753.001]
  • [Cites] J Neurooncol. 2006 Nov;80(2):133-42 [16941076.001]
  • [Cites] Mol Biol Cell. 2006 Dec;17(12):5141-52 [16987961.001]
  • [Cites] Mol Cell Neurosci. 2007 Mar;34(3):453-67 [17234431.001]
  • [Cites] Mol Cell Neurosci. 2007 Mar;34(3):481-92 [17276081.001]
  • [Cites] Nat Protoc. 2006;1(3):1165-71 [17406399.001]
  • [Cites] Cancer Res. 2007 Aug 1;67(15):7203-11 [17671188.001]
  • [Cites] Genes Dev. 2007 Nov 1;21(21):2683-710 [17974913.001]
  • [Cites] Annu Rev Pathol. 2006;1:97-117 [18039109.001]
  • [Cites] Mol Cancer Res. 2008 Jul;6(7):1106-13 [18644975.001]
  • [Cites] Nat Rev Mol Cell Biol. 2008 Aug;9(8):603-15 [18648374.001]
  • [Cites] N Engl J Med. 2008 Jul 31;359(5):492-507 [18669428.001]
  • [Cites] Semin Radiat Oncol. 2001 Apr;11(2):103-12 [11285548.001]
  • [Cites] J Biol Chem. 2001 May 4;276(18):14896-901 [11278757.001]
  • [Cites] Cancer Res. 2001 Jun 1;61(11):4612-9 [11389098.001]
  • [Cites] J Neurosci Res. 2001 Nov 1;66(3):487-96 [11746367.001]
  • [Cites] Mol Cell Neurosci. 2002 Feb;19(2):292-306 [11860281.001]
  • [Cites] Neurosurgery. 2003 Jan;52(1):187-96; discussion 196-7 [12493117.001]
  • [Cites] J Clin Oncol. 2003 Apr 15;21(8):1624-36 [12697889.001]
  • [Cites] J Neurobiol. 2003 Sep 5;56(3):199-208 [12884260.001]
  • [Cites] Dev Neurosci. 2003 Mar-Aug;25(2-4):207-16 [12966218.001]
  • [Cites] Mol Cell Neurosci. 2004 Apr;25(4):558-71 [15080886.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2004 Jun;75 Suppl 2:ii2-11 [15146033.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 May 18;101(20):7618-23 [15128949.001]
  • [Cites] Expert Opin Ther Targets. 2004 Jun;8(3):211-20 [15161428.001]
  • [Cites] Dev Biol. 2004 Nov 1;275(1):12-22 [15464569.001]
  • [Cites] Cancer Res. 1984 Feb;44(2):753-60 [6318976.001]
  • [Cites] Cytometry. 1992;13(1):48-59 [1372202.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Apr 1;89(7):2965-9 [1557402.001]
  • [Cites] Cell. 1992 Aug 7;70(3):401-10 [1643658.001]
  • [Cites] J Biol Chem. 1993 Aug 5;268(22):16101-4 [8393854.001]
  • [Cites] J Cell Biol. 1993 Aug;122(4):961-72 [8394372.001]
  • [Cites] Breast Cancer Res Treat. 2004 Mar;84(1):13-9 [14999150.001]
  • (PMID = 19304959.001).
  • [ISSN] 1523-5866
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / R01 NS051520-04; United States / NEI NIH HHS / EY / P30 EY011373; United States / NINDS NIH HHS / NS / R01 NS051520; United States / NINDS NIH HHS / NS / R01-NS051520; United States / NCI NIH HHS / CA / K08 CA101954; United States / NINDS NIH HHS / NS / NS051520-04; United States / NEI NIH HHS / EY / P30 EY011373-119002; United States / NCI NIH HHS / CA / P20 CA103736; United States / NEI NIH HHS / EY / P30 EY011373-129002; United States / NCI NIH HHS / CA / P30 CA043703; United States / NEI NIH HHS / EY / P30 EY011373-139002; United States / NCI NIH HHS / CA / T32 CA059366; United States / NINDS NIH HHS / NS / NS051520-02; United States / NINDS NIH HHS / NS / NS051520-01A1; United States / NEI NIH HHS / EY / EY011373-139002; United States / NIGMS NIH HHS / GM / T32-GM007250; United States / NEI NIH HHS / EY / P30-EY11373; United States / NEI NIH HHS / EY / EY011373-119002; United States / NINDS NIH HHS / NS / NS051520-03; United States / NINDS NIH HHS / NS / R01 NS051520-02; United States / NINDS NIH HHS / NS / R01 NS051520-01A1; United States / NEI NIH HHS / EY / EY011373-129002; United States / NCI NIH HHS / CA / K08-CA101954; United States / NCI NIH HHS / CA / R01-CA116257; United States / NCI NIH HHS / CA / P30-CA043703; United States / NCI NIH HHS / CA / T32-CA059366; United States / NCI NIH HHS / CA / R01 CA116257; United States / NIGMS NIH HHS / GM / T32 GM007250; United States / NINDS NIH HHS / NS / R01 NS051520-03; United States / NCI NIH HHS / CA / P20-CA103736
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / RNA, Small Interfering; EC 3.1.3.48 / Receptor-Like Protein Tyrosine Phosphatases, Class 2
  • [Other-IDs] NLM/ PMC2802397
  •  go-up   go-down


77. Naranjo C, Schobert C, Dubielzig R: Canine ocular gliomas: a retrospective study. Vet Ophthalmol; 2008 Nov-Dec;11(6):356-62
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • One neoplasm was classified as low-grade astrocytoma, 5 tumors as medium-grade astrocytoma, 11 tumors as high grade-astrocytoma and 1 tumor as oligodendroglioma.
  • The metastatic potential appears to be low, but ascending invasion into the ventral aspect of the brain is possible.

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19046275.001).
  • [ISSN] 1463-5224
  • [Journal-full-title] Veterinary ophthalmology
  • [ISO-abbreviation] Vet Ophthalmol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein
  •  go-up   go-down


78. Hardell L, Carlberg M, Mild KH: Case-control study of the association between the use of cellular and cordless telephones and malignant brain tumors diagnosed during 2000-2003. Environ Res; 2006 Feb;100(2):232-41
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The OR increased with the cumulative number of hours of use and was highest for high-grade astrocytoma.
  • A somewhat increased risk was also found for low-grade astrocytoma and other types of malignant brain tumors, although not significantly so.
  • [MeSH-major] Astrocytoma / etiology. Brain Neoplasms / etiology. Cell Phones

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16023098.001).
  • [ISSN] 0013-9351
  • [Journal-full-title] Environmental research
  • [ISO-abbreviation] Environ. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


79. Vajtai I, Arnold M, Kappeler A, Jeless O, Lukes A, Mariani L, Paulus W: Rosette-forming glioneuronal tumor of the fourth ventricle: report of two cases with a differential diagnostic overview. Pathol Res Pract; 2007;203(8):613-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • On microscopy, both tumors comprised an admixture of low-grade astrocytoma interspersed with circular aggregates of synaptophysin-expressing round cells harboring oligodendrocyte-like nuclei.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17651910.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein; 0 / Synaptophysin
  •  go-up   go-down


80. Beaty O 3rd, Berg S, Blaney S, Malogolowkin M, Krailo M, Knight R, Schaiquevich P, Stewart C, Chen Z, Nelson M, Voss S, Ivy SP, Adamson PC: A phase II trial and pharmacokinetic study of oxaliplatin in children with refractory solid tumors: a Children's Oncology Group study. Pediatr Blood Cancer; 2010 Sep;55(3):440-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histologies included: Ewing sarcoma/peripheral PNET, osteosarcoma, rhabdomyosarcoma, neuroblastoma, high and low grade astrocytoma, brain stem glioma, ependymoma, hepatoblastoma and selected rare tumors.
  • A two-stage design, enrolling 10 + 10 subjects, was used for each disease stratum.
  • An additional 13 subjects with various other solid tumors had stable disease, receiving a median (range) of 13.5 (2-17) cycles.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Wiley-Liss, Inc.
  • (PMID = 20658614.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U10CA98413; United States / NCI NIH HHS / CA / U10CA98543; United States / NCI NIH HHS / CA / U10 CA098413; United States / NCI NIH HHS / CA / U10 CA098543-08; United States / NCI NIH HHS / CA / U10 CA098543; United States / NCI NIH HHS / CA / U10 CA098413-08
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin
  • [Other-IDs] NLM/ NIHMS218622; NLM/ PMC4665115
  •  go-up   go-down


81. Stockhammer F, Misch M, Horn P, Koch A, Fonyuy N, Plotkin M: Association of F18-fluoro-ethyl-tyrosin uptake and 5-aminolevulinic acid-induced fluorescence in gliomas. Acta Neurochir (Wien); 2009 Nov;151(11):1377-83
Hazardous Substances Data Bank. L-TYROSINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histology revealed glioblastomas in 11 cases, an anaplastic astrocytoma in one case and a low-grade astrocytoma in one case.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19639250.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Austria
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / O-(2-fluoroethyl)tyrosine; 42HK56048U / Tyrosine; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


82. Combs SE, Bischof M, Welzel T, Hof H, Oertel S, Debus J, Schulz-Ertner D: Radiochemotherapy with temozolomide as re-irradiation using high precision fractionated stereotactic radiotherapy (FSRT) in patients with recurrent gliomas. J Neurooncol; 2008 Sep;89(2):205-10
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histologic classification at primary diagnosis included low-grade astrocytoma in 7 patients (28%), grade III gliomas in 10 patients (40%) and glioblastoma in 8 patients (32%).

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2005 Dec 1;23(34):8863-9 [16314646.001]
  • [Cites] Am J Clin Oncol. 1997 Jun;20(3):226-9 [9167741.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Nov 15;54(4):1114-20 [12419438.001]
  • [Cites] Br J Cancer. 2003 Sep 1;89(5):781-6 [12942105.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Oct 1;69(2):381-9 [17513061.001]
  • [Cites] J Clin Oncol. 2006 Jun 1;24(16):2563-9 [16735709.001]
  • [Cites] Br J Cancer. 2003 Jul 21;89(2):232-8 [12865907.001]
  • [Cites] Strahlenther Onkol. 2005 Jun;181(6):372-7 [15925979.001]
  • [Cites] Can J Surg. 1993 Jun;36(3):271-5 [8391917.001]
  • [Cites] J Clin Oncol. 1999 Sep;17 (9):2762-71 [10561351.001]
  • [Cites] Cancer Invest. 1996;14(6):551-9 [8951359.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Mar 1;43(4):789-93 [10098434.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Jul 1;29(4):719-27 [8040017.001]
  • [Cites] J Clin Oncol. 2007 Aug 1;25(22):3357-61 [17664483.001]
  • [Cites] Neurosurgery. 1987 Nov;21(5):615-21 [2827052.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Jul 30;29(5):1147-55 [8083085.001]
  • [Cites] Cancer. 2005 Nov 15;104(10):2168-73 [16220556.001]
  • [Cites] Am J Clin Oncol. 2000 Apr;23(2):155-9 [10776976.001]
  • [Cites] Br J Cancer. 2000 Sep;83(5):588-93 [10944597.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Sep 1;36(2):433-41 [8892469.001]
  • [Cites] Cancer. 2005 Dec 1;104(11):2473-6 [16270316.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10 ):987-96 [15758009.001]
  • (PMID = 18461281.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; YF1K15M17Y / temozolomide
  •  go-up   go-down


83. Talos IF, Zou KH, Kikinis R, Jolesz FA: Volumetric assessment of tumor infiltration of adjacent white matter based on anatomic MRI and diffusion tensor tractography. Acad Radiol; 2007 Apr;14(4):431-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: There were five patients with low-grade oligodendroglioma (WHO Grade II), one with low-grade mixed oligoastrocytoma (WHO Grade II), one with ganglioglioma, two with low-grade astrocytoma (WHO Grade II), and three with anaplastic astrocytoma (WHO Grade III).

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Magn Reson Imaging. 2001 Jun;13(6):967-75 [11382961.001]
  • [Cites] AJNR Am J Neuroradiol. 2006 Oct;27(9):1969-74 [17032877.001]
  • [Cites] Ann Neurol. 2002 Mar;51(3):377-80 [11891834.001]
  • [Cites] J Clin Oncol. 2002 Apr 15;20(8):2076-84 [11956268.001]
  • [Cites] Med Image Anal. 2002 Jun;6(2):93-108 [12044998.001]
  • [Cites] J Neurosurg. 2002 Sep;97(3):568-75 [12296640.001]
  • [Cites] NMR Biomed. 2002 Nov-Dec;15(7-8):468-80 [12489096.001]
  • [Cites] J Neurosurg. 2002 Dec;97(6):1333-42 [12507131.001]
  • [Cites] Neurosurgery. 2004 Aug;55(2):358-70; discussion 370-1 [15271242.001]
  • [Cites] Radiology. 2004 Aug;232(2):451-60 [15215555.001]
  • [Cites] J Neurosurg. 1987 Jun;66(6):865-74 [3033172.001]
  • [Cites] Cancer. 1994 Apr 1;73(7):1937-45 [8137221.001]
  • [Cites] Surg Neurol. 1995 Sep;44(3):208-21; discussion 221-3 [8545771.001]
  • [Cites] Neurosurgery. 1996 Apr;38(4):678-84; discussion 684-5 [8692384.001]
  • [Cites] Neurosurgery. 1996 Aug;39(2):253-8; discussion 258-9 [8832661.001]
  • [Cites] J Neurooncol. 1997 Aug;34(1):37-59 [9210052.001]
  • [Cites] J Comput Assist Tomogr. 1997 Jul-Aug;21(4):554-66 [9216759.001]
  • [Cites] Brain Res. 1998 Jan 5;780(1):27-33 [9473573.001]
  • [Cites] Med Image Anal. 1996 Mar;1(1):35-51 [9873920.001]
  • [Cites] Clin Neurol Neurosurg. 2005 Apr;107(3):174-80 [15823671.001]
  • [Cites] Radiology. 2005 Aug;236(2):615-20 [16040917.001]
  • [Cites] Cancer. 2006 Mar 15;106(6):1358-63 [16470608.001]
  • [Cites] Radiology. 2006 Apr;239(1):217-22 [16484348.001]
  • [Cites] Neurosurgery. 2006 Apr;58(4 Suppl 2):ONS-292-303; discussion ONS-303-4 [16582653.001]
  • [Cites] Radiology. 2006 May;239(2):506-13 [16641355.001]
  • [Cites] J Neurooncol. 2006 Jun;78(2):179-85 [16739029.001]
  • [Cites] Neuroimage. 2006 Sep;32(3):1127-33 [16798013.001]
  • [Cites] J Neurosurg. 2001 Nov;95(5):735-45 [11702861.001]
  • (PMID = 17368212.001).
  • [ISSN] 1076-6332
  • [Journal-full-title] Academic radiology
  • [ISO-abbreviation] Acad Radiol
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / P41 RR013218-098542; United States / NCRR NIH HHS / RR / U41 RR019703; United States / NIGMS NIH HHS / GM / R01 GM074068; United States / NCRR NIH HHS / RR / U41 RR019703-03S1; United States / NIBIB NIH HHS / EB / P41 EB015898; United States / NLM NIH HHS / LM / R01 LM007861; United States / NCRR NIH HHS / RR / P41 RR013218-02; United States / NCRR NIH HHS / RR / RR019703-03S1; United States / NCRR NIH HHS / RR / P41 RR013218; United States / NCRR NIH HHS / RR / RR013218-108434; United States / NCRR NIH HHS / RR / RR013218-098542; United States / NCI NIH HHS / CA / P01 CA067165; United States / NCRR NIH HHS / RR / P41 RR013218-108434
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS21072; NLM/ PMC2397554
  •  go-up   go-down


84. Said HM, Stein S, Hagemann C, Polat B, Staab A, Anacker J, Schoemig B, Theobald M, Flentje M, Vordermark D: Oxygen-dependent regulation of NDRG1 in human glioblastoma cells in vitro and in vivo. Oncol Rep; 2009 Jan;21(1):237-46
Hazardous Substances Data Bank. OXYGEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In our study, differences in NDRG1 expression between different WHO grades of astrocytic tumors were comparatively examined in vivo in human low-grade astrocytoma (WHO grade 2) and glioblastoma (WHO grade 4) at both the protein and mRNA level by Western blot analysis and semi-quantitative RT-PCR, respectively.
  • This regulation was shown at the same levels in vivo in human low-grade astrocytoma (WHO grade 2) and glioblastoma which showed a higher NDRG1 overexpression level in glioblastoma than in low-grade astrocytoma. siRNA- and iodoacetate (IAA)-mediated downregulation of NDRG1 mRNA and protein expression in vitro in human glioblastoma cell lines showed a nearly complete inhibition of NDRG1 expression when compared to the results obtained due to the inhibitory role of glycolysis inhibitor IAA.

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19082468.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / HIF1A protein, human; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / Intracellular Signaling Peptides and Proteins; 0 / N-myc downstream-regulated gene 1 protein; 0 / RNA, Messenger; 0 / RNA, Small Interfering; S88TT14065 / Oxygen
  •  go-up   go-down


85. Ohgaki H, Kleihues P: Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol; 2005 Jun;64(6):479-89
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • While survival rates for pilocytic astrocytomas were excellent (96% at 10 years), the prognosis of diffusely infiltrating gliomas was poorer, with median survival times (MST) of 5.6 years for low-grade astrocytoma WHO grade II, 1.6 years for anaplastic astrocytoma grade III, and 0.4 years for glioblastoma.
  • For oligodendrogliomas the MSTwas 11.6 years for grade II and 3.5 years for grade III.
  • Primary (de novo) glioblastomas prevailed (95%), while secondary glioblastomas that progressed from low-grade or anaplastic gliomas were rare (5%).
  • [MeSH-major] Astrocytoma. Brain Neoplasms. Loss of Heterozygosity. Oligodendroglioma. Tumor Suppressor Protein p53 / genetics
  • [MeSH-minor] Age Distribution. Chromosomes, Human, Pair 10. Disease Progression. Humans. Incidence. Mutation. Predictive Value of Tests. Recurrence. Sex Factors. Survival Rate. Switzerland / epidemiology


86. Yang S, Yang X, Hong G: Surgical treatment of one hundred seventy-four intramedullary spinal cord tumors. Spine (Phila Pa 1976); 2009 Nov 15;34(24):2705-10
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: In this group ependymoma was the commonest tumor (48.9%), the second most often seen being astrocytoma (35.6%).
  • In low grade astrocytoma total resection was possible in 41.1%, subtotal in 35.1%, and partial resection in 23.2%.
  • [MeSH-major] Astrocytoma / surgery. Ependymoma / surgery. Neurosurgical Procedures / methods. Spinal Cord Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19910775.001).
  • [ISSN] 1528-1159
  • [Journal-full-title] Spine
  • [ISO-abbreviation] Spine
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


87. Boss A, Bisdas S, Kolb A, Hofmann M, Ernemann U, Claussen CD, Pfannenberg C, Pichler BJ, Reimold M, Stegger L: Hybrid PET/MRI of intracranial masses: initial experiences and comparison to PET/CT. J Nucl Med; 2010 Aug;51(8):1198-205
Hazardous Substances Data Bank. (L)-Methionine .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Diagnoses at the time of referral were low-grade astrocytoma (n = 2), suspicion of low-grade astrocytoma (n = 1), anaplastic astrocytoma (World Health Organization grade III; n = 1), glioblastoma (n = 2), atypical neurocytoma (n = 1), and meningioma (n = 3).

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20660388.001).
  • [ISSN] 1535-5667
  • [Journal-full-title] Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • [ISO-abbreviation] J. Nucl. Med.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Gallium Radioisotopes; 0 / Radiopharmaceuticals; AE28F7PNPL / Methionine; RWM8CCW8GP / Octreotide; U194AS08HZ / Edotreotide
  •  go-up   go-down


88. Pirotte BJ, Lubansu A, Massager N, Wikler D, Van Bogaert P, Levivier M, Brotchi J, Goldman S: Clinical interest of integrating positron emission tomography imaging in the workup of 55 children with incidentally diagnosed brain lesions. J Neurosurg Pediatr; 2010 May;5(5):479-85
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histological examination results demonstrated neither malignant nor evolving tumor tissue but yielded 9 indolent tumors (6 dysembryoplastic neuroectodermal tumors, 2 low-grade astrocytomas, and 1 low-grade astrocytoma and dysplasia) and 7 nontumoral lesions (3 cases of vasculitis, 3 of gliosis, and 1 of sarcoidosis).
  • In 22 of the untreated 38 children, stable disease was noted during follow-up (range 18-136 months).
  • Nowadays, it is estimated that these data justify conservative management in incidental lesions with low or absent PET tracer uptake.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • Hazardous Substances Data Bank. (L)-Methionine .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20433262.001).
  • [ISSN] 1933-0715
  • [Journal-full-title] Journal of neurosurgery. Pediatrics
  • [ISO-abbreviation] J Neurosurg Pediatr
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carbon Radioisotopes; 0Z5B2CJX4D / Fluorodeoxyglucose F18; AE28F7PNPL / Methionine; BN630929UL / methionine methyl ester
  •  go-up   go-down


89. McCall T, Rao G, Jensen R: Development and rapid growth of a desmoid tumor in the surgical corridor after suboccipital craniotomy for recurrent low-grade astrocytoma. J Neurooncol; 2006 Nov;80(2):167-70
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development and rapid growth of a desmoid tumor in the surgical corridor after suboccipital craniotomy for recurrent low-grade astrocytoma.
  • We present the rare case of a desmoid tumor that occurred in the surgical corridor after suboccipital craniotomy for recurrent low-grade astrocytoma.
  • A 30-year-old woman underwent a repeat suboccipital craniotomy for recurrent low-grade astrocytoma.
  • Histology demonstrated clear surgical margins and a tumor of low cellularity consistent with a desmoid tumor.
  • [MeSH-major] Astrocytoma / surgery. Brain Neoplasms / pathology. Fibromatosis, Aggressive / pathology. Postoperative Complications / pathology

  • Genetic Alliance. consumer health - Desmoid Tumor.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 1973 Jul;39(1):114-6 [4717135.001]
  • [Cites] Cancer. 1960 Jul-Aug;13:825-36 [14405434.001]
  • [Cites] Clin Orthop Relat Res. 2000 Jun;(375):207-13 [10853171.001]
  • [Cites] Cancer. 1999 Nov 15;86(10):2045-52 [10570430.001]
  • [Cites] Orthop Rev. 1987 Jul;16(7):481-8 [3331192.001]
  • [Cites] Acta Chir Scand. 1979;145(8):563-9 [539343.001]
  • [Cites] Arch Surg. 2001 Jan;136(1):70-9 [11146782.001]
  • [Cites] Am J Surg. 1966 Oct;112(4):615-22 [5915310.001]
  • [Cites] Tumori. 2005 Jul-Aug;91(4):325-30 [16277098.001]
  • [Cites] Neurosurgery. 1999 Oct;45(4):875-81; discussion 881-2 [10515483.001]
  • [Cites] Br J Surg. 1995 Apr;82(4):510-4 [7613897.001]
  • [Cites] Arch Surg. 1989 Feb;124(2):191-6 [2916941.001]
  • [Cites] Cancer. 1984 Nov 15;54(10):2051-5 [6488135.001]
  • [Cites] Radiology. 1977 Jul;124(1):225-6 [405711.001]
  • [Cites] Cancer. 1967 Jul;20(7):1131-40 [6027003.001]
  • [Cites] Am J Clin Pathol. 1982 Jun;77(6):674-80 [7091047.001]
  • [Cites] J Bone Joint Surg Am. 1996 Jun;78(6):848-54 [8666602.001]
  • [Cites] Surgery. 1969 Feb;65(2):241-6 [4237097.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Sep 1;36(2):325-8 [8892455.001]
  • [Cites] Ann Surg. 1999 Jun;229(6):866-72; discussion 872-3 [10363901.001]
  • [Cites] Br J Surg. 2000 May;87(5):608-13 [10792318.001]
  • [Cites] J Surg Oncol. 2004 Jun 1;86(3):152-6 [15170654.001]
  • [Cites] Surgery. 1964 Sep;56:497-504 [14215706.001]
  • [Cites] Am J Surg. 1988 Oct;156(4):327-31 [3177760.001]
  • [Cites] Head Neck. 2000 Dec;22(8):814-21 [11084643.001]
  • [Cites] Am J Hum Genet. 1962 Dec;14:376-90 [13946545.001]
  • [Cites] J Bone Joint Surg Am. 1984 Dec;66(9):1369-74 [6501332.001]
  • [Cites] J Thorac Cardiovasc Surg. 1963 Aug;46:242-51 [14049009.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1983 Aug;9(8):1167-71 [6409853.001]
  • [Cites] World J Surg Oncol. 2005 Jul 21;3:49 [16042767.001]
  • [Cites] Arch Pathol. 1961 Feb;71:214-21 [13706852.001]
  • (PMID = 16645711.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


90. Stosić-Opinćal T, Gavrilov M, Stosić S, Lavrnić S, Perić V, Grujicić D: [FLAIR MR sequence in the diagnosis and follow-up of low-grade astrocytomas]. Vojnosanit Pregl; 2005 Jul-Aug;62(7-8):525-8
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [FLAIR MR sequence in the diagnosis and follow-up of low-grade astrocytomas].
  • AIM: To evaluate the sensitivity of fluid-attenuated inversion recovery (FLAIR) sequence in the diagnosis and follow-up of the patients with low-grade astrocytomas compared with T2-weighted (T2W) sequence.
  • METHODS: Twenty-four patients with biopsy-confirmed low-grade astrocytoma (age range, 15-66 years) underwent T1-weighted (T1W), T2W and FLAIR imaging with a superconducting unit 1.0 T.
  • CONCLUSION: Our results were similar to the previous studies' results concerning the advantages of FLAIR sequence in the diagnosis of low grade astrocytomas over T2W sequence.
  • Our conclusion was that FLAIR could be routinely used in the evaluation and follow-up of low-grade astrocytomas.
  • [MeSH-major] Astrocytoma / diagnosis. Brain Neoplasms / diagnosis. Magnetic Resonance Imaging

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16171014.001).
  • [ISSN] 0042-8450
  • [Journal-full-title] Vojnosanitetski pregled
  • [ISO-abbreviation] Vojnosanit Pregl
  • [Language] srp
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Serbia and Montenegro
  •  go-up   go-down


91. Fernandez A, Karavitaki N, Ansorge O, Fazal-Sanderson V, Wass JA: Acromegaly and anaplastic astrocytoma: coincidence or pathophysiological relation? Pituitary; 2008;11(3):325-30
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acromegaly and anaplastic astrocytoma: coincidence or pathophysiological relation?
  • We report the case of a 28-year-old man who presented simultaneously with acromegaly and an anaplastic astrocytoma, which had rapidly progressed from a low-grade astrocytoma.
  • The coexistence of systemic IGF-I hypersecretion with a quick progression in the histopathological grade of the astrocytoma raises the compelling question of whether the clinical behavior of the astrocytic tumor was influenced by the acromegalic status.
  • [MeSH-major] Acromegaly / complications. Astrocytoma / complications. Brain Neoplasms / complications
  • [MeSH-minor] Adult. Cranial Irradiation. Craniotomy. Disease Progression. Ergolines / therapeutic use. Humans. Insulin-Like Growth Factor I / metabolism. Magnetic Resonance Imaging. Male. Neoplasm Staging. Peptides, Cyclic / therapeutic use. Somatostatin / analogs & derivatives. Somatostatin / therapeutic use. Treatment Outcome. Up-Regulation

  • Genetic Alliance. consumer health - Acromegaly.
  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Brain Pathol. 1993 Jul;3(3):255-68 [8293185.001]
  • [Cites] Horm Metab Res. 1999 Feb-Mar;31(2-3):114-9 [10226790.001]
  • [Cites] Cancer Res. 1991 Oct 1;51(19):5107-12 [1717138.001]
  • [Cites] Ann Neurol. 1992 Apr;31(4):431-6 [1586143.001]
  • [Cites] Neurosurgery. 1998 Jan;42(1):172-8 [9442520.001]
  • [Cites] J Neurooncol. 1997 Aug;34(1):31-5 [9210051.001]
  • [Cites] Eur J Endocrinol. 2003 Nov;149(5):377-92 [14585082.001]
  • [Cites] Cancer Res. 1994 Apr 15;54(8):2218-22 [8174129.001]
  • [Cites] J Neurooncol. 1997 Dec;35(3):315-25 [9440028.001]
  • [Cites] J Clin Oncol. 2002 Apr 15;20(8):2076-84 [11956268.001]
  • [Cites] Neurosurgery. 1992 Oct;31(4):636-42; discussion 642 [1407448.001]
  • [Cites] BMC Cancer. 2002 May 31;2:15 [12057025.001]
  • [Cites] Neuro Oncol. 1999 Apr;1(2):109-19 [11550306.001]
  • [Cites] Lancet. 2004 Apr 24;363(9418):1346-53 [15110491.001]
  • [Cites] Clin Endocrinol (Oxf). 2001 Dec;55(6):731-3 [11895213.001]
  • [Cites] Growth Horm IGF Res. 2001 Apr;11(2):84-91 [11472074.001]
  • [Cites] J Clin Endocrinol Metab. 1990 Jul;71(1):199-209 [2164527.001]
  • [Cites] Endocr Rev. 2005 Dec;26(7):916-43 [16131630.001]
  • [Cites] J Neuropathol Exp Neurol. 2004 Jan;63(1):13-9 [14748557.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Dec;91(12):4769-75 [16968795.001]
  • [Cites] Clin Cancer Res. 1999 May;5(5):1025-33 [10353735.001]
  • [Cites] Exp Cell Res. 1988 Jun;176(2):336-43 [2837402.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Dec;85(12):4444-9 [11134091.001]
  • [Cites] Cancer Res. 1987 Nov 1;47(21):5758-64 [2889527.001]
  • [Cites] Endocr Rev. 2004 Feb;25(1):102-52 [14769829.001]
  • [Cites] Neurosurgery. 2003 Jun;52(6):1391-9; discussion 1399 [12762884.001]
  • [Cites] Neurosurgery. 1996 Dec;39(6):1243-5; discussion 1245-6 [8938782.001]
  • [Cites] Neurobiol Dis. 2000 Dec;7(6 Pt B):657-65 [11114263.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Jul;87(7):3136-41 [12107213.001]
  • [Cites] Endocr Rev. 2000 Jun;21(3):215-44 [10857553.001]
  • [Cites] Brain Res Dev Brain Res. 2002 Mar 31;134(1-2):115-22 [11947942.001]
  • (PMID = 18000757.001).
  • [ISSN] 1386-341X
  • [Journal-full-title] Pituitary
  • [ISO-abbreviation] Pituitary
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ergolines; 0 / Peptides, Cyclic; 0G3DE8943Y / lanreotide; 51110-01-1 / Somatostatin; 67763-96-6 / Insulin-Like Growth Factor I; LL60K9J05T / cabergoline
  •  go-up   go-down


92. Saunders DE, Phipps KP, Wade AM, Hayward RD: Surveillance imaging strategies following surgery and/or radiotherapy for childhood cerebellar low-grade astrocytoma. J Neurosurg; 2005 Mar;102(2 Suppl):172-8
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surveillance imaging strategies following surgery and/or radiotherapy for childhood cerebellar low-grade astrocytoma.
  • OBJECT: The authors sought to evaluate surveillance strategies for the detection and monitoring of residual and recurrent disease in children with cerebellar low-grade astrocytomas (CLGAs) treated surgically or with radiotherapy.
  • (2) those with residual disease with no immediate adjuvant therapy; and (3) those who received radiotherapy for residual/recurrent disease.
  • [MeSH-major] Astrocytoma / diagnosis. Cerebellar Neoplasms / diagnosis. Magnetic Resonance Imaging. Neoplasm, Residual / diagnosis. Tomography, X-Ray Computed
  • [MeSH-minor] Adolescent. Cerebellum / pathology. Cerebellum / radiography. Cerebellum / surgery. Child. Child, Preschool. Disease Progression. Female. Follow-Up Studies. Humans. Infant. Male. Neoplasm Recurrence, Local / epidemiology. Neoplasm Staging. Postoperative Care. Remission, Spontaneous. Time Factors

  • Genetic Alliance. consumer health - Cerebellar Astrocytoma, Childhood.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16156227.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


93. Hidaka T, Hama S, Shrestha P, Saito T, Kajiwara Y, Yamasaki F, Sugiyama K, Kurisu K: The combination of low cytoplasmic and high nuclear expression of p27 predicts a better prognosis in high-grade astrocytoma. Anticancer Res; 2009 Feb;29(2):597-603
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The combination of low cytoplasmic and high nuclear expression of p27 predicts a better prognosis in high-grade astrocytoma.
  • No previous reports have examined the subcellular localization of p27 in glioma which was evaluated here regarding the prognosis in high-grade astrocytomas.
  • PATIENTS AND METHODS: The pattern of subcellular localization of p27 expression was examined immunohistochemically in 49 patients with high-grade astrocytoma who were over 20 years of age.
  • Cox multiple regression analysis showed the combination of high nuclear and low cytoplasmic p27 expression associated with a significantly better prognosis in high-grade astrocytoma.
  • CONCLUSION: A combination of low cytoplasmic and high nuclear expression of p27 predicts a better prognosis in high-grade astrocytomas and thus the subcellular localization of p27 expression is useful for predicting the prognosis for these patients.
  • [MeSH-major] Astrocytoma / metabolism. Biomarkers, Tumor / biosynthesis. Brain Neoplasms / metabolism. Cyclin-Dependent Kinase Inhibitor p27 / biosynthesis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19331209.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27
  •  go-up   go-down


94. Matsuda K, Sakurada K, Mouri W, Saino M, Sato S, Saito S, Kayama T, Nakazato Y: [Operative case of isomorphic astrocytoma]. Brain Nerve; 2007 Aug;59(8):881-6
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Operative case of isomorphic astrocytoma].
  • Diffuse astrocytomas are classified as WHO Grade II tumors.
  • Recently, a subtype presenting with better prognosis has been proposed, and it is known as "isomorphic astrocytoma."
  • The pathological diagnosis was diffuse astrocytoma, but this tumor was considered to be the isomorphic subtype.
  • Isomorphic astrocytoma is characterized by prolonged epileptic seizures, a low MIB-1 LI, and better prognosis.
  • In our case, since the MIB-1 LI was higher in some parts of the tumor, the appropriate therapy for WHO Grade II tumors was performed.
  • However, this case was considered representative of isomorphic astrocytoma.
  • Therefore, this report is the first case of isomorphic astrocytoma reported to Japanese literature.
  • [MeSH-major] Astrocytoma / surgery. Brain Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17713125.001).
  • [ISSN] 1881-6096
  • [Journal-full-title] Brain and nerve = Shinkei kenkyū no shinpo
  • [ISO-abbreviation] Brain Nerve
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


95. Della Puppa A, Zustovich F, Gardiman M, Manara R, Cecchin D, Scienza R: Haemorrhagic presentation of low-grade glioma in adults. Acta Neurochir (Wien); 2007 Nov;149(11):1151-5; discussion 1155
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Haemorrhagic presentation of low-grade glioma in adults.
  • Intracranial bleeding is rare in patients with low-grade gliomas, above all in adult population.
  • We reviewed the literature of such cases and reported another case of a haemorrhagic low-grade glioma in a 54-year-old woman presenting with a left hemiparesis.
  • Late magnetic resonance images revealed a low-grade glioma at the bleeding site.
  • Tumour was removed and histopathologic examination revealed a WHO grade II mixed glioma.
  • [MeSH-major] Astrocytoma / diagnosis. Basal Ganglia Diseases / diagnosis. Basal Ganglia Hemorrhage / etiology. Brain Neoplasms / diagnosis. Magnetic Resonance Imaging. Positron-Emission Tomography. Putaminal Hemorrhage / etiology. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17676407.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Austria
  • [Number-of-references] 22
  •  go-up   go-down


96. Nakasu S, Fukami T, Jito J, Matsuda M: Prognostic significance of loss of O6-methylguanine-DNA methyltransferase expression in supratentorial diffuse low-grade astrocytoma. Surg Neurol; 2007 Dec;68(6):603-8; discussion 608-9
Genetic Alliance. consumer health - Diffuse Astrocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of loss of O6-methylguanine-DNA methyltransferase expression in supratentorial diffuse low-grade astrocytoma.
  • [MeSH-major] Astrocytoma / metabolism. Astrocytoma / pathology. Biomarkers, Tumor / metabolism. O(6)-Methylguanine-DNA Methyltransferase / metabolism. Supratentorial Neoplasms / metabolism. Supratentorial Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Cell Transformation, Neoplastic. Child. Disease Progression. Female. Humans. Immunohistochemistry. Male. Middle Aged. Prognosis. Retrospective Studies. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17825378.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase
  •  go-up   go-down


97. Durmaz R, Vural M, Işildi E, Coşan E, Ozkara E, Bal C, Ciftçi E, Arslantaş A, Atasoy MA: Efficacy of prognostic factors on survival in patients with low grade glioma. Turk Neurosurg; 2008 Oct;18(4):336-44
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of prognostic factors on survival in patients with low grade glioma.
  • AIM: In this report, we aim to determine the prognostic factors influencing the length of survival in patients with low-grade gliomas.
  • The diagnoses of the patients were histopathologically verified as low-grade glioma(LGG).
  • Median survival time was 216+/-78.52 months for astrocytoma Grade I; 115+/-8.22 months for astrocytoma Grade II, and 242+/-76.36 months for oligodendroglioma.
  • [MeSH-minor] Adolescent. Adult. Aged. Aging. Astrocytoma / mortality. Astrocytoma / pathology. Astrocytoma / surgery. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Kaplan-Meier Estimate. Karnofsky Performance Status. Magnetic Resonance Imaging. Male. Middle Aged. Neurosurgical Procedures. Oligodendroglioma / mortality. Oligodendroglioma / pathology. Oligodendroglioma / surgery. Prognosis. Reoperation. Retrospective Studies. Seizures / etiology. Survival. Tomography, X-Ray Computed. Young Adult

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19107679.001).
  • [ISSN] 1019-5149
  • [Journal-full-title] Turkish neurosurgery
  • [ISO-abbreviation] Turk Neurosurg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


98. Gaiser T, Becker MR, Meyer J, Habel A, Siegelin MD: p53-mediated inhibition of angiogenesis in diffuse low-grade astrocytomas. Neurochem Int; 2009 Jun;54(7):458-63
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p53-mediated inhibition of angiogenesis in diffuse low-grade astrocytomas.
  • In this study we evaluated the associations of p53 status and vessel density (angiogenesis) in a set of diffuse low-grade astrocytomas.
  • Immunohistochemistry was performed on 23 diffuse low-grade astrocytomas for CD31 and p53.
  • However, the MVD was significantly increased in p53 mutated low-grade astrocytomas.
  • Furthermore, the absolute vessel number was significantly higher in p53 mutated than in p53 wild-type low-grade astrocytomas.
  • The higher microvessel density and the increased absolute vessel number in p53 mutated tumours supports the importance of p53 for tumour angiogenesis in diffuse low-grade astrocytomas.
  • Our results support the hypothesis that p53 regulates angiogenesis in low-grade astrocytomas.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Neovascularization, Pathologic / pathology. Tumor Suppressor Protein p53 / physiology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19428789.001).
  • [ISSN] 1872-9754
  • [Journal-full-title] Neurochemistry international
  • [ISO-abbreviation] Neurochem. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


99. Watanabe T, Katayama Y, Yoshino A, Yachi K, Ohta T, Ogino A, Komine C, Fukushima T: Aberrant hypermethylation of p14ARF and O6-methylguanine-DNA methyltransferase genes in astrocytoma progression. Brain Pathol; 2007 Jan;17(1):5-10
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant hypermethylation of p14ARF and O6-methylguanine-DNA methyltransferase genes in astrocytoma progression.
  • The aim of the present study was to elucidate genetic alterations that are critically involved in astrocytoma progression.
  • We characterized 27 World Health Organization grade II fibrillary astrocytomas which later underwent recurrence or progression, paying specific attention to the CpG island methylation status of critical growth regulatory genes. p14(ARF) and O(6)-methylguanine-DNA methyltransferase (MGMT) hypermethylation represented frequent events (26% and 63%, respectively), which were mutually exclusive except in one case, with alternate or simultaneous methylation of these two genes occurring in 85% of our tumor series.
  • Methylation of the p21(Waf1/Cip1), p27(Kip1) and p73 genes and homozygous deletion of the p16(INK4a), p15(INK4b) and p14(ARF) genes were not detected in any of the primary low-grade tumors.
  • On analysis of their respective recurrent tumors, five of six patients whose primary low-grade tumors carried p14(ARF) methylation exhibited homozygous co-deletions of the p14(ARF), p15(INK4b) and p16(INK4a) genes, which were restricted to glioblastoma as the most malignant end point.
  • Our findings suggest that p14(ARF) hypermethylation and MGMT hypermethylation constitute distinct molecular pathways of astrocytoma progression, which could differ in biological behavior and clinical outcome.
  • [MeSH-major] Astrocytoma / metabolism. Brain Neoplasms / metabolism. CpG Islands / physiology. Neoplasm Recurrence, Local / metabolism. O(6)-Methylguanine-DNA Methyltransferase / metabolism. Tumor Suppressor Protein p14ARF / metabolism

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17493032.001).
  • [ISSN] 1015-6305
  • [Journal-full-title] Brain pathology (Zurich, Switzerland)
  • [ISO-abbreviation] Brain Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p14ARF; 0 / Tumor Suppressor Protein p53; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase
  •  go-up   go-down


100. Chatley A, Jaiswal AK, Jain M, Behari S: Congenital irreducible atlantoaxial dislocation associated with cervical intramedullary astrocytoma causing progressive spastic quadriparesis. Neurol India; 2008 Oct-Dec;56(4):477-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Congenital irreducible atlantoaxial dislocation associated with cervical intramedullary astrocytoma causing progressive spastic quadriparesis.
  • Simultaneous presence of congenital irreducible atlantoaxial dislocation (AAD) and cervical intramedullary astrocytoma has not been previously described and may cause disabling myelopathy.
  • Histopathology revealed a low-grade astrocytoma.
  • Thus, the suboccipital craniectomy and laminectomy with midline myelotomy and duroplasty facilitated space for progressively expanding intramedullary astrocytoma with irreducible AAD; the lateral mass fixation provided stability at the craniovertebral junction.
  • [MeSH-major] Astrocytoma / complications. Atlanto-Axial Joint. Dislocations / complications. Dislocations / congenital. Quadriplegia / etiology. Spinal Neoplasms / complications

  • MedlinePlus Health Information. consumer health - Dislocations.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19127046.001).
  • [ISSN] 0028-3886
  • [Journal-full-title] Neurology India
  • [ISO-abbreviation] Neurol India
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down






Advertisement